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Abstract 
 
Although phage display-based enrichments became a standard procedure, they still suffer from 
some drawbacks. Nonspecific phage binding limits the enrichment that can be achieved per se-
lection round and therefore, in most cases, at least three or four rounds are required to identify the 
antigen binding nanobodies (Nbs) from the library. Moreover, the release of the phages captured 
via their antigen-specific Nb on the immobilized antigen is accomplished most often, by a pH 
shock that will also release the a-specific absorbed phages, thereby generating an unwanted back-
ground. However, the biggest shortcoming is the difficulty to identify the Nb of best binding 
affinity. We now have to ferment and purify all individual Nb clones to homogeneity and measure 
their affinity parameters one after the other. This is very tedious, certainly, as the identified Nbs 
often share a high degree of amino acid sequence identity, which makes it impossible to predict 
the one having the best affinity. The objective of this thesis aimed to modify the phage display 
vector so that one round of selection will be sufficient, while the affinity of all antigen-positive 
Nbs can be compared immediately after ELISA. 
Firstly, a vector containing the Calmodulin Binding Peptide (CBP) tag was created, by substitut-
ing the hemagglutinin (HA) tag present in a pMECS-GG plasmid by the CBP tag. Moreover, 6 
Nbs with well-known and variable kinetic binding rates were also inserted into the vector 
pMECS-CBP. 
Next, the vector was used in a phage display setting, where two mini libraries comprising the 6 
Nbs were made. One library had the conventional pMECS vector while the other was made using 
the pMECS-CBP vector. Although an enrichment of 1000 times was achieved using pMECS, 
pMECS-CBP failed to show any enrichment, supporting the hypothesis that Nb-CBP encountered 
serious expression problems. To investigate the validity of this hypothesis, periplasmic expression 
of Nb-CBP was performed and compared with that of the Nb without the tag. While the Nb 
yielded almost 4 mg per liter of culture media, the Nb-CBP could only be obtained at 0.63 mg 
per liter culture. Moreover, the Nb-CBP couldn’t be detected on a western blot. Several methods 
were used, such as adding lysozyme to improve the periplasmic extraction step, expressing 5 
different colonies to check if there was a homogeneity of expression between them. In all meth-
ods, the amount produced always remained below 1 mg per liter and Nb-CBP protein couldn’t be 
detected in any step of expression by Coomassie stained SDS-PAGE or western blot. 
Additionally, a high yield expressing-protein (SIRPα) was cloned into the CBP vector to identify 
whether the expression problem was caused by the peptide tag itself or by the Nb-CBP combina-
tion. Even though SIRPα was obtained at a yield of 8.7 mg/L of culture when expressed from a 
vector not containing the CBP, its expressed yield using the CBP vector, dropped to 0.7 mg/L of 
culture, indicating that the CBP tag is incompatible with good periplasmic expression. 
Lastly, a nucleotide alignment of our CBP tag with a previously reported one, revealed differences 
in two Arginine codons, two Alanine codons and one Lysine codon. Moreover, our sequence 
employed two codons, AGA and CGG, rarely used in E. coli, which might be linked to the re-
duced expression levels that we observed during this thesis.  
Keywords: Phage Display, Nanobodies, Periplasmic Protein Expression 
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Resumo 
 
Apesar dos enriquecimentos através de phage display se terem tornado um procedimento habitual, 
ainda possuem alguns inconvenientes. As ligações inespecíficas dos fagos limitam o enriqueci-
mento que pode ser atingido por ronda de seleção e, dessa forma, pelo menos três a quatro rondas 
são necessárias para identificar os nanocorpos de uma biblioteca que se ligam ao antigénio. Além 
disso, a libertação dos fagos capturados através do seu nanocorpo específico para antigénio imo-
bilizado é frequentemente realizada por um choque de pH, que também irá libertar os fagos ab-
sorvido inespecificamente, gerando background indesejado. No entanto, o maior inconveniente é 
a dificuldade em identificar o nanocorpo com melhor afinidade. Neste momento, tem que se pro-
duzir e purificar todos os clones individualmente e medir os seus parâmetros de afinidade um 
após o outro. Isto é muito trabalhoso, uma vez que, com frequência, os nanocorpos apresentam 
sequências de aminoácidos idênticas, o que torna impossível prever qual poderá ter melhor afini-
dade para o alvo. Esta tese foi criada com o objetivo de modificar o vetor de phage display, para 
que apenas uma ronda de seleção seja necessária, enquanto a afinidade de todos os nanocorpos 
que se liguem positivamente ao antigénio possa ser comparada imediatamente após ELISA. 
Primeiro, um vetor que contivesse uma tag do péptido de ligação à calmodulina (CBP) foi criado, 
através da substituição da tag da hemaglutinina contida no plasmídeo pMECS-GG. Além disso, 
6 nanocorpos com constantes de ligação variáveis e bem estabelecidas, foram também inseridos 
no vetor pMECS-CBP. 
De seguida, o novo vetor foi usado em phage display, onde duas mini bibliotecas compostas por 
6 nanocorpos foram criadas. Uma das bibliotecas continha o vetor pMECS convencional, en-
quanto a outra foi construída usando o vetor pMECS-CBP. Apesar de um enriquecimento de 1000 
vezes ter sido observado usando o pMECS, o vetor pMECS-CBP não apresentou qualquer enri-
quecimento, sustentando a hipótese de que os nanocorpos conjugados com o CBP teriam proble-
mas de expressão. Para perceber a veracidade desta hipótese, expressão periplasmática dos nano-
corpos conjugados com o CBP foi realizada e comparada com a dos nanocorpos sem a tag. En-
quanto na expressão dos nanocorpos mais de 5 mg por litro de cultura foram produzidos, a ex-
pressão dos nanocorpos conjugados com o CBP apenas obteve 0,63 mg por litro de cultura. Para 
além disso, os nanocorpos conjugados não foram detetados via western blot. Outros métodos fo-
ram testados, tais como a adição de lisozima para melhorar a fase de extração periplasmática e a 
expressão de 5 colónias diferentes de cada nanocorpo para verificar se havia uma homogeneidade 
de expressão entre elas. Em todas as tentativas, a quantidade produzida permaneceu sempre 
abaixo de 1 mg e os nanocorpos conjugados com o CBP não conseguiam ser detetados em ne-
nhuma fase da expressão usando SDS-PAGE e western blot. 
Posteriormente, uma proteína com elevada expressão (SIRPα) foi clonada no vetor pMECS-CBP, 
para perceber se o problema de expressão era causado pela tag peptídica ou pela conjugação 
nanocorpo e CBP. Apesar de o SIRPα ter produzido 8,7 mg/L de cultura quando expresso com o 
vetor que não continha o CBP, a quantidade produzida usando o vetor pMECS-CBP baixou para 
0,7 mg/L de cultura, indicando que a tag CBP é incompatível com uma boa expressão periplas-
mática. 
Por fim, um alinhamento de nucleótidos entre o CBP tag utlizado e outro previamente descrito, 
revelou diferenças entre dois codões de Arginina, dois codões de Alanina e um codão de Lisina. 
Notou-se ainda que a sequência usada no decorrer desta tese continha dois codões, AGA e CGG, 
raramente usados em E. coli, o que pode estar ligado aos reduzidos valores de expressão obser-
vados no decorrer da tese. 
Palavras-chave: Phage Display, Nanocorpos, Expressão periplasmática de proteína 
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1 Introduction 
1.1 Phage Display 
Phage display, firstly introduced by G. Smith in 1985 1, is a well-established molecular screening 
technique whereby a library of genes with a randomized region is expressed and exposed as pep-
tide or protein on the surface of bacteriophages that are available for selection 2. Its advantages 
include being robust, easy to perform, highly versatile and inexpensive 3. 
The unique feature of the method relies on the physical linkage that is established between the 
genotype and the phenotype of the phage particle 2. A ligand’s coding sequence of interest is fused 
to the sequence of one of the phage coat proteins and, after expression and subsequent incorpora-
tion of this new vector on phages, the ligand is presented on its surface, while having the corre-
sponding genetic material inside 4. This critical linkage allows a rapid analysis and identification 
(when compared with other techniques), after selection, of the phage particles with the desired 
binding specificities 5. 
Usually, there are 5 key steps involved in phage display (Figure 1.1). It all starts with the con-
struction of a library, which is crucial since the final results will directly depend on the quality of 
the designed library 6. Then, the specific ligands of the library will be retrieved, typically via 
biopanning, which will select them based on their expression level and the capacity to recognize 
the target 7. Usually, 3 to 5 cycles of biopanning are required to enrich the clones of highest 
affinity 8. The clones with highest affinity are identified after re-amplification and production of 
their ligand in Echerichia coli (E. coli). Finally, experiments are performed to confirm the speci-
ficity, to measure the affinity parameters and to reveal the sequence of the selected ligand 8. 
 
Figure 1.1 - Illustration of the key steps involved in phage display 8. 
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Phage display can have diverse applications, such as: studies of protein-protein interactions 9, 
epitope mapping 10, identification of mimic epitopes (mimotopes) 11, discovery and development 
of new biological drugs 12, in vivo imaging of tumors 13 and improvement or modification of 
affinity of proteins to their binding partners 14. This allowed major breakthroughs in the field of 
immunology, cell biology, pharmacology and drug discovery 2. In recognition of these major 
achievements, half of the Nobel Prize in Chemistry was awarded in 2018 to George Smith and 
Sir Greg Winter “for the phage display of peptides and antibodies” 15. 
1.1.1 Phage Display Vectors 
Bacteriophages, are viruses that can infect a variety of Gram-negative bacteria 6. Different bacte-
riophage DNA can be used as phage display vector to transform or infect E. coli, such as T4, T7, 
lambda and filamentous phages, the latter being the preferred one 4.  
Among E.coli-infective filamentous bacteriophages, the most used and best studied group is the 
nonlytic F pilus-specific phages (also known as Ff), which include the strains M13, f1 and fd 16. 
This group is closely related, being 98.5% identical in their DNA sequence, and infect male E. 
coli  after a specific interaction between the phage and the tip of the F-pilus produced by the 
bacteria 8 17. Since they are nonlytic phages, the assembly is done in the periplasmic environment 
and then they are secreted out of the bacterial cell 4. Although the growth rate of the bacteria 
decreases significantly, they survive phage infection 4. 
There are some unique characteristics that make filamentous bacteriophages suitable vectors for 
phage display 4. The infections can be controlled, since these phages infect only E. coli strains 
that express the F-pilus 4. Moreover, since there is an immediate depolymerization of the F-pilus 
after infection, a bacterium can only be infected once, thus each bacterium secretes a unique phage 
with the encoded peptide 4. Larger foreign sequences inserted in the phage genome simply results 
in the production of longer phage particles, since DNA replication and the assembly of phages is 
not limited by the size of the inserted DNA sequence 4 17. Filamentous phages are stable under a 
variety of very harsh conditions, such as extreme pH, high and low temperatures, presence of 
DNase, enzymatic cleavage and nonaqueous solutions 4 6 18. 
We will limit ourselves to the description of M13 as it is the most widely used and considered the 
model of filamentous bacteriophages 8 19. 
1.1.1.1 M13 Bacteriophage Structure 
M13 has a semi-flexible, extended tube-like shape (Figure 1.2A), with 6.5 nm in diameter and 
900 nm long 3 8 19. The phage contains a genome of single-stranded DNA (ssDNA) with 6407 bp, 
consisting of 9 genes encoding 11 different proteins (Figure 1.2B) 3. These proteins are grouped 
according to their function, five of them are coat proteins, major coat protein (pVIII) and minor 
coat proteins (pIII, pVI, pVII and pIX), while the other six are involved in replication (pII, pV, 
and pX)  and assembly/secretion of the phage (pI, pIV and pXI) 3 20. 
 
 
 
 
 
 
 
 
 
Figure 1.2 – A - Structure of M13 bacteriophage. Adapted from 16. B – Schematic representation of Ff bacteriophages 
genome with the function of each gene. Adapted from 21. 
A B 
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M13 consists of 2700 copies of the major coat protein pVIII, a 50 amino acids (aa) residue protein, 
which polymerizes along the length of the genome 4 8. The minor coat proteins are located in pairs 
at each tip of the phage 8. At one end of the virion, there are 5 molecules of each hydrophobic 
proteins: pVII, a 33 aa residue protein, and pIX, a 32 aa residue protein 19. The other end contains 
5 copies each of the pIII (406 aa residue protein) and the pVI (112 aa residue protein) 19. These 
last two proteins are required for the structural stability, completion of assembly and release of 
the virion 16. 
1.1.1.2 M13 Bacteriophage Life Cycle 
Upon infection of  F+ E. coli strains, M13 induces a state in which the infected bacteria produce 
and secrete new phage virions into the growth medium (Figure 1.3) 6. 
 
Figure 1.3 - Life Cycle of M13 bacteriophage 16. 
Infection is initiated with the adsorption process, occurring by the attachment of the N2 domain 
of pIII to the tip of the F-pilus 3. When the phage binds the F-pilus, a depolymerization of the 
pilus will occur, bringing the virion closer to the surface of the bacterium and allowing the N1 
domain of pIII to bind TolA located between the inner and outer membranes of the host cell 3. 
Although it is understood that the complex TolQRA present in E. coli, containing the proteins 
TolA, TolR and TolQ, is essential for infection and translocation of the ssDNA into the bacterium, 
the exact contribution of this complex is still unknown 3 8. It is only established that this sequence 
of events, involving pIII binding, contraction of pili and virion passage through the outer mem-
brane, will end up at the injection of the circular ssDNA M13 genome, referred to as infective 
form (IF), into the host cytoplasm 4 8 21. Inside the host, the bacterial DNA synthesis machinery 
will synthetize a DNA strand complementary to the ssDNA to produce circular supercoiled dou-
ble-stranded DNA (dsDNA), also known as replicative form (RF) 3. The replication starts when 
pII cleaves the ori site in the RF (+) strand and binds covalently to its 5’ end 3 4. The exposed 3’ 
end serves as a primer and will be elongated by the DNA polymerase using the (-) strand as a 
template 3 4. After the replication completes a full circle, pII nicks and ligates the free ends, re-
sulting in a ssDNA IF and dsDNA RF 21. In the early stages of infection, the IF is converted in 
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new RF and the production of RFs, via rolling cycle replication (described above), continues, 
until pV is expressed in sufficient levels to sequester the IF 4 21. Late in the infection, the high 
level of pV inhibits both the RF production and the translation of pII and pX, which leads to the 
accumulation of the IF 21. Although the exact mechanism remains unclear, pX plays an essential 
role in the stable accumulation of IF 3. Moreover, pV starts to bind to the IF, leading to the change 
of the circular appearance of the ssDNA to a more rod shaped appearance and initiating the virion 
assembly 3 8. The entire IF is covered with pV, except for an exposed hairpin loop, the packing 
signal, which is required for packing of phage genome 3. Assembly is initiated by the binding of 
pVII and pIX to the packing signal, which occurs in the inner membrane of the host 21. Then, the 
pV is replaced by pVIII, until the entire phage genome is coated with the major capsid protein 
and pIII and pVI bind the virion and allow its release from the bacterium 3 21. This process of 
phage secretion involves ATP hydrolysis and the complete phages are extruded through the mem-
brane channels created by pII and pIV complex 4. 
As mentioned before, M13 assembly is a nonlytic process, therefore newly assembled mature 
virions will continuously be extruded from the infected host, which continue to grow and divide, 
even if at a reduced rate (a generation time of around 50% longer than for uninfected bacteria) 17 
19. Moreover, taking into consideration that there is a lack of replication regulation and an ability 
of the episome to be transferred to daughter cells during cellular division, it is expected that the 
viral stock reaches a high titer (~1013 phages /ml of culture) 8. 
1.1.1.3 Phage or Phagemid? 
While phage DNA can be used as a cloning vector, sometimes it is advantageous to mix 
interesting features of phages with that of bacterial plasmids to arrive at chimeric phagemid 
vectors. Phage display can be performed using phage or phagemid vectors, however since they 
have different properties they result in different kinds of display 8. 
Ligand’s genes can be cloned directly into the phage genome that includes the origin of replication 
and all essential genes required for propagation 8. As a result, all phage particles will contain only 
the viral genome and will display the peptide in all coat proteins choosen for the display, which 
usually results in multivalent display (except when proteolysis degradation results in loss of some 
of the displayed peptide) 3 22. 
In the case of using phagemids, there are three key elements to consider: 1) an antibiotic resistance 
marker for the selection and propagation of the wanted phages, 2) the gene encoding the displayed 
ligand, 3) all the M13 genome elements essential for replication and assembly of phages 3. 
Phagemids contain the replication origins of both, an E. coli plasmid and M13, in conjunction 
with an antibiotic resistance marker 17. Moreover, it usually incorporates an amber stop codon 
between the C-terminus of the cloned gene and the start of the capsid protein gene, allowing for 
an easy switch between the production of a fusion protein or autonomous soluble protein 17. A 
peptide tag is encoded as well, which can be used, at later stage of phage display, for purification 
methods of the desired ligands 17. Having these characteristics, the phagemid can produce a large 
amount of the recombinant displayed ligand, however it is unable to produce phages unless the 
bacterium is co-infected with a helper phage 22. The helper phage, such as M13KO7 or VSCM13, 
carries all the genes necessary for the infection, replication and assembly of phage particles 3. An 
antibiotic resistance marker is also encoded and a truncated origin of replication, which ensures 
a preferential packaging of the phagemid DNA over the helper phage genome 8 23. Employing a 
phagemid usually results in monovalent display of the ligand, which is desired when ligands of 
highest intrinsic affinity are required, without having to worry about avidity effects 8. 
Most of the times, phagemids are preferred over phage vectors for library constructions, due to 
their higher transformation efficiencies that lead to larger and more diverse libraries 3 18. The 
variety of restriction enzyme sites present in phagemids facilitates gene manipulation, simplifying 
the cloning processes of the recombinant peptides 18. Also, phagemids tend to be genetically more 
stable after multiple rounds of propagation, due to relative resistance to deletions of extraneous 
genetic material, when compared with recombinant phages 18 22. 
5 
 
A list of properties that have to be considered when choosing between phage or phagemid vectors 
to create a phage display library that is suitable for a specific goal is summarized in Table 1.1. 
Table 1.1 – Advantages and disadvantages of each vector for GIII phage display 22. 
Phage Phagemid 
GIII mutated phage first 
round, normal subsequent 
Three to five copies of Ab per 
phage 
Only 1-10% of phagemids have 
one copy of the displayed Ab 
Three to five copies of Ab per 
phage 
Difficult to transfect and make 
DNA 
Easy to handle Easy to handle 
Faster to select and easier to use 
Slower to select (helper phage 
needed) 
Slower to select (helper phage 
needed) 
Must subclone to make soluble 
Ab 
Soluble Ab made directly Soluble Ab made directly 
Phenotypic and genotypic homo-
geneity 
Phenotypic and genotypic heter-
ogeneity 
Phenotypic and genotypic heter-
ogeneity 
Genetically less stable (dele-
tions) 
More stable genetically More stable genetically 
Greater diversity of Abs selected Lower diversity of Abs selected 
Greater diversity of Abs proba-
bly selected 
Lower affinity Abs also selected 
due to avidity effects 
Higher affinity Abs selected due 
to monomeric display 
Selection can be directed to-
wards higher affinity Abs 
Not suitable for affinity matura-
tion due to avidity effects 
Better for affinity maturation 
May be suitable for affinity mat-
uration 
1.1.2 Phage Display Systems 
Since the discovery of phage display, all M13 coat proteins have already been explored as possi-
ble display platforms (Figure 1.5) 8. Depending on the capsid protein, multiple configurations can 
be achieved on the displayed peptide/protein 8. 
 
Figure 1.4 - M13 Phage Display Systems 8. 
The density of display will depend on which coat protein the ligand is attached 8. For high-density 
display, the major coat is used, since it has a high number of copies 8. However, the size of the 
ligand will have a major influence on the density level that can be accomplished due to steric 
hinderance 8. Usually only peptides with 6-7 residues can guarantee unbiased display in pVIII 
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systems, so if a peptide is larger, a wild-type pVIII has to be present as well 16. Furthermore, the 
density can also be controlled by the availability of wild-type pVIII proteins during virion assem-
bly (more pVIII wild-type, less density) 8. In the minor coat proteins, valency is also controlled 
by presence or absence of wild-type coat protein 8. Moreover, fusions of the encoded recombinant 
peptides can be done to N-, C- or both termini, nevertheless this will depend on structural and 
functional constraints 8.  
Selection of the system to use will be dependent on the aims that one wants to achieve with the 
technique. To increase the chances of selecting ligands, usually a high density and polyvalent 
display is preferred 8. In cases where avidity has an impact on retrieving specific targets, a poly-
valent display is required 17. However, if highest affinity ligands are required, monovalent dis-
plays on the minor coat proteins are preferred 17.  
Although all coat proteins can be used as a display platform, most of the times pIII and pVIII are 
preferred 17. When comparing both systems, pIII display tolerates larger ligand fusions and has a 
better performance 17. 
1.1.3 Types of Displayed Ligands 
Depending on the specific aims of the study undertaken, two types of displayed ligands are widely 
used – peptides and antibodies (Abs) 24. 
Random peptide libraries are generally constructed using (NNK)n codon degeneracy, where N is 
an equimolar of all four nucleotides and K is a 1:1 mixture of guanine and thymine 24. This de-
creases the number of stop codons that can appear in the randomization, since there is a reduction 
of the number of stop codons that can be formed from three to one (TAG, the amber stop codon) 
24. These libraries are inserted at the N-terminal of the coat proteins and range between 6 and 43 
aa in length, since longer peptides can possibly interfere with the infectious activity or capsid 
assembly of the virion 25. 
Since Abs, such as IgG, are quaternary structures, with a size of 150 kDa, composed of two heavy 
and two light chains, each with variable and constant domains, it is very challenging for bacteria 
to express into functional proteins 8 15. Moreover, their display on the surface of phages, is seri-
ously compromised due to limitations in the bacteria folding machinery 17. Therefore, Ab libraries 
created to replace conventional immunization and hybridoma techniques, involve the design of 
combinatorial libraries of heavy-chain variable domains (VH) and light-chain variable domains 
(VL) from B lymphocytes, which are ligated as a pair in a phagemid 8 25. Apparently, these dis-
played, smaller, monovalent Ab fragments retain the affinity properties of intact Abs 15. 
1.1.3.1 Antibody Fragments and Nanobodies 
Several Ab formats (Figure 1.5) were already used for the construction of libraries, with each one 
having advantages and limitations (Table 1.2) 26. 
 
Figure 1.5 - Types of antibody fragments that can be displayed on the surface of bacteriophages 8. 
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The first two types of Ab fragments successfully displayed on the surface of bacteriophages were 
antigen-binding fragments (Fab) and single-chain variable fragments (scFv) 17.  
Fabs are composed of the full length of variable regions of heavy and light chains (VH and VL), 
as well as a constant region for each chain (CH1 and CL) linked by a disulfide bond 8 27. They 
have a tendency to form homodimers which interfere in finding the fragment with highest affinity 
27. However, if the final goal is to find Abs that bind to a specific target, these fragments are a 
good solution 24. Fabs possess better stability, pharmacokinetic and pharmacodynamic properties 
when compared to scFvs 28. The main disadvantage of using Fab libraries is their lower expression 
level in E.coli since there is a chance of producing toxic material to the cell (due to the large size 
of the fragments), in comparison with scFv 24. 
An scFv is composed of the variable regions VH and VL, connected by a flexible serine-glycine 
linker to mimic the binding cavity upon folding 24 27. Additionally, this linker serves the purpose 
of increasing the folding, flexibility and stability, as well as the solubility of the fragment 24 27. 
These fragments are smaller than Fabs, what make them advantageous in imaging, since they can 
penetrate tissues much more rapidly and efficiently 26. Moreover, due to their small size, scFv are 
easier to clone and can bind to cryptic or sterically restricted epitopes 17 26. Yet, their main disad-
vantage is their propensity to aggregate, which can interfere with selection and characterization 
17. Furthermore, scFv’s tend to become unstable when stored over prolonged periods of time 17. 
These two Ab fragments might also be engineered and converted into other formats with different 
characteristics that can be used, as well, for libraries (Table 1.2) 26. Even though scFv and Fab 
fragments are significantly less complex than conventional Abs, it is still challenging to produce 
them, due to their requirement of proper domain association 8. 
Table 1.2 – Characteristics of different antibody formats 26. 
Antibody format Size (kDa) Paratope (valency) Fc mediated functions 
IgG 150 2 Yes 
scFv 28 1 No 
Fab 50 1 No 
F(ab)2 110 2 No 
scFv-Fc 110 2 Yes 
Diabody 55 2 No 
Single domain antibody (VHH) 15 1 No 
A major breakthrough in the generation of Ab phage display libraries was the discovery of natu-
rally occurring functional heavy chain only antibodies (HCAbs) in sera of Camelids by Hamers 
and colleagues 8 29. HCAbs lack light chains, as well as the first constant domain (CH1), so the 
antigen association occurs solely with the heavy chain variable region (VHH) 30. The designation 
VHH was introduced to emphasize the differences between the heavy chain variable regions in 
camelids and conventional Abs 31. Even though both contain four conserved framework regions 
and three CDR regions, their general consensus is somewhat different (Figure 1.6) 32. Further-
more, key hydrophobic amino acids of framework-2 involved in binding the VL region in con-
ventional Abs are substituted by hydrophilic or smaller residues conferring VHH solubility and 
explaining the absence of VL association 32. In comparison with VH, VHH have also an extended 
CDR1 and longer CDR3, consequently having the ability to adopt novel paratope conformations 
for antigen recognition 32.  
VHH, also known as nanobodies (Nbs), are characterized by their small size (15 kDa),  high 
thermal stability and solubility, resistance to denaturation, ease of manipulation, high affinity and 
specificity (similar to conventional Abs), higher tissue penetration and low immunogenicity 31 33. 
Moreover, they are expressed to a high level in bacterial organisms, routinely with yields of sev-
eral milligrams per liter of culture 30. 
The generation of Nb libraries involves the immunization of camelids with a cocktail of antigens 
(Ags), the isolation of mRNA from peripheral blood lymphocytes and synthesis of cDNA by 
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reverse transcription 33. Nbs, with an encoded gene of around 360bp, can, then, be amplified by 
polymerase chain reaction (PCR) and ligated into a cloning vector 33. 
 
Figure 1.6 – Schematic representation of the sequence organization of the VH versus VHH with frameworks and 
CDRs. The crucial amino acid substitutions in framework-2 are described. Adapted from 30 
1.1.4 Selection Methods 
The selection of phage displayed libraries aims to enrich clones that recognize a target or Ag of 
interest 34. Briefly, it involves phage binding to the target, washes to remove nonspecific phages 
and elution to retrieve specific binding phages 17. Ideally only one round of selection should be 
enough, however due to limitations of enrichment and nonspecific phage binding 3 to 5 rounds 
of selection are required to obtain the best clones from a library 34.  
There are some important considerations to keep in mind while planning a selection. To reduce 
nonspecific phage binding, it is important to use a suitable protein-binding site blocking agent, as 
well as Tween-20 during the washing step 22. Moreover, the first selection round should not be 
too stringent to ensure that all binding phages are recovered for subsequent amplification, includ-
ing those present in very few copies 22. Selections on impure Ags are more challenging, since 
there is a chance of enriching phages specific for non-relevant Ags 34. 
Various methods can be envisaged, whereby different strategies can be designed to drive selection 
into the required direction by controlling specific criteria (Figure 1.7) 17. These strategies can be 
separated in two groups: those which attempt to isolate binders against a known Ag and those 
which use phage binders as a research tool to target unknown Ags 22. Although the outcome of a 
selection process depends on the quality of the constructed library, the biopanning strategy influ-
ences the ability to select clones not only with the required affinity and specificity, but also phys-
ical properties and functionality 17. In Figure 1.7, the most popular strategies are listed on the top 
(panels A-E), including biopanning on immobilized Ag coated on solid supports or columns, bi-
opanning in solution with biotinylated Ags and selection on cells 35. 
Biopanning on immobilized Ag coated on plastic surfaces by (passive) adsorption is the preferred 
selection procedure 25. Biopanning involves following steps 22 25 (see Figure 1.1, 2. Library 
screening):  
1) Ag immobilization: The Ag can be immobilized by passive adsorption to a modified 96-well 
polystyrene microtiter plates. The unbound Ag is washed away, and the residual protein binding 
sites in the well is saturated with a blocking agent, such as BSA or (semi-)skimmed milk powder; 
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2) Phage binding: The phage display library is added to an Ag coated well. For a better chance of 
isolating the best binders, it is important to start the first round with a large and highly variable 
library; 
3) Removing unbound phage: In the first round the washes are shorter and less stringent, to re-
cover a high yield of the fittest phage clones over the background. The stringency of selection is 
increased in subsequent rounds by more extensive and longer washes to isolate phage with higher 
affinity; 
4) Phage elution: The specific elution of the target bound phage can be performed in solution 
either with free target or a competing ligand. Taking advantage of phage stability, extreme pH, 
denaturants, ionic strength, limited proteolysis or sonication can be used for non-specific elution 
of the antigen bound phage.  
The eluted phage is amplified and the biopanning process is repeated 25. During this process, the 
enrichment achieved per round is monitored to evaluate the efficiency and to understand if a 
redesign of the strategy might be needed for selection of the better binders 17. 
 
Figure 1.7 - Selection strategies for obtaining specific phage ligands. A – Affinity selection from libraries by biopan-
ning on Ag absorbed onto a solid support, such as wells in microtiter plates. B – After washing, the specific binders 
can be eluted with acidic or basic solutions, as well as with Ab or excess of Ag. C – to avoid conformational changes 
during coating, selections on biotinylated Ag captured on coated streptavidin are preferred. D – the Ag can also be 
immobilized on Sepharose and loaded onto columns for affinity selection. E – Panning directly on cell monolayers or 
cell suspensions can also be used as a selection strategy. F- In this type of selection the cells of interest are fluores-
cently labeled and separated from the others by cell sorting. G – Tissue or organ specific binders can be obtained by 
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selection on tissue slides. H – Non-purifiable or unknown Ags may be separated on SDS-PAGE and blotted onto 
membranes for selection. I – Selection in vivo is also possible. J – Pathfinder selection. K – Infection-mediated selec-
tion 35. 
A particular problem of direct adsorption of Ag onto solid surfaces is that the epitope may be 
partially denatured or hidden, when the adsorption provokes conformational changes in the Ag 17 
22. This may lead to selection of binders that don’t recognize the native Ag, particularly for small-
size Ags 17 22. Even though this is not a common event, it can be avoided by presenting the Ag in 
solution, via biotinylated Ag, and by any other indirect coating 17 22. 
1.1.5 Screening Methods 
Once the selection procedure is complete, a fast and robust screening assay of individual clones 
is required, such as Enzyme Linked Immunosorbent Assay (ELISA),  Fluorescence-Activated 
Cell Sorting (FACS), nucleotide sequencing and immunocyto- or histochemistry 22. 
For a first screen, ELISA-based assays in combination with PCR and restriction fragment poly-
morphism of the Ab-encoding DNA are typically performed to narrow the potential candidate 
clones to the best and different candidates 22 35. ELISA is a biochemical assay that uses Abs and 
an enzyme-mediated color change to detect the presence of either Ag or Ab in a given sample 36. 
In this case, usually an anti-M13 phage Ab and either Alkaline Phosphatase (AP) or Horseradish 
Peroxidase (HRP) are used for the detection 37. The Ab expression level in E. coli is dependent 
on its primary sequence and can be extremely variable, making it impossible to correlate the af-
finity parameters with the signal intensity obtained from ELISA 22. A positive binding event can 
either be due to a high affinity or a high expression level (or both) 38. Thus, it is necessary to 
develop a screening assay that differentiates between clone variants that differ in affinity or in the 
kinetics of binding 35. The determination of dissociation rates to differentiate among the clones is 
performed using sophisticated instruments such as BIAcore or Octet 17. 
Additional screening methods might be carried out for a better characterization of the binders 
regarding their specificity, functionality and stability 17. 
After screening assays, it is important to sequence all the positive binders and clone them into 
vectors suitable for mass production 17 22. 
1.2 Calmodulin 
Calmodulin (CaM) is a small (17 kDa, comprised by 148 aa residues), well-conserved protein 
with a key role in intracellular signal transduction 39 40. CaM participates in signaling pathways 
by interacting with a variety of proteins, including kinases, phosphatases, ion channels and cyto-
skeleton proteins 40 41. It plays important roles in muscle contraction, cell proliferation, inflam-
mation, learning and memory, exo- and endocytoses, immune response and growth 40 41. 
CaM is a dumbbell-shape protein consisting of two lobes, N-lobe and C-lobe, connected by a 
highly flexible helical linker that allows a variety of conformations when bound to different tar-
gets 40 42. Each lobe contains a pair of EF-hand motifs which allow the binding of four Ca2+ ions, 
followed by a change of conformation from a hydrophilic structure to a more hydrophobic state 
that allows CaM to bind amphipathic α-helices in target proteins with very high affinity 39 40 41 42. 
Most of the times, the binding is reversible by the addition of calcium chelators, making this 
system an interesting candidate for biotechnological applications 39. 
1.2.1 Calmodulin Binding Peptide 
The CaM binding proteins are a large group of proteins that don’t show amino acid sequence 
homology, however can share unique structural features, such as an α-helical propensity, specific 
distribution of hydrophobic residues (two hydrophobic anchor residues spaced by a certain num-
ber of aa) and net positive charge (Figure 1.8) 43. 
Among these CaM binding proteins is a peptide residue of 19 aa (RWKKAFIAVSAANRFKKIS) 
derived from wild type skeletal muscle myosin light chain kinase 39 44. This CaM binding peptide 
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(CBP) has an ultra-high affinity (KD 2 pM) promoted by a mutation on N5A 44. This affinity 
enhancement guarantees that the CBP can resist vigorous washing steps and can be released from 
the immobilization substrate by addition of a calcium chelator, such as EDTA 44. Moreover, it has 
been shown that when fused into a target, it does not affect its expression 44. 
 
Figure 1.8 - Schematic representation of the interaction between calmodulin and the calmodulin binding peptide. Pro-
vided by Prof. Dr. Serge Muyldermans. 
1.3 Description of the New Phage Display Selection Approach 
Based on the binding properties between CaM and CBP 44, as well as studies with biotinylated 
Nbs that aim to normalize the captured amount 38, a new approach for phage display was devel-
oped (Figure 1.9 and Figure 1.10). 
 
Figure 1.9 - Schematic representation of new biopanning approach. 
First a new biopanning method will be developed (Figure 1.9). An Ag-CBP fusion from crude 
extracts will be captured by CaM indirectly adsorbed into microtiter plate using a buffer contain-
ing Ca2+ and impurities will be washed away. Then, we will add the phage particles rescued from 
the pMECS-CBP library carrying Nbs from an immunized camelid. Since all CaM are already 
loaded with Ag-CBP, it is expected that the phages will not be captured on CaM, but instead via 
their affinity for the captured Ag. After a short incubation and a few washes, a buffer with EDTA 
will be added, to release only those phages that were binding to the Ag via their Nb. Consequently, 
it is expected that the a-specific-bounded phage particles will not be disrupted, remaining attached 
into the wells and reducing the amount of background generated. For this reason, it is thought that 
one single round or maximum two consecutive rounds of panning might be sufficient, instead of 
three to five rounds using classical phage display and pH shock elution. A fraction of the eluted 
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pMECS-CBP virions will be used to infect WK6 cells, which will be grown individually and 
induce the expression of Nb-CBP in the periplasm. 
After obtaining individual Nb-CBP fusion proteins, a screening modified method of PE-ELISA 
will be developed (Figure 1.10). The Nb-CBP fusion proteins from a crude periplasmic extract 
will be captured on a limited and fixed amount of CaM, immobilized on wells of microtiter plates, 
in presence of Ca2+ ions. After washing away the impurities, the Nb-CBP (a fixed amount corre-
sponding to the moles of CaM coated in the wells) will be rescued by a short incubation with a 
buffer containing EDTA. Then, this Nb-CBP will be added to a well coated with Ag, followed by 
the addition of alkaline phosphatase fused with CaM in the presence of a calcium-containing 
buffer. In the presence of AP substrate, the ELISA signal will be monitored. Since a fixed amount 
of binder is used for ELISA, the discrepancies between expression levels of the different clones 
are no longer taken into account, so it is expected that the signal from ELISA will directly corre-
late with the affinity parameters. To verify if this correlation exists, 6 Nbs with well-established 
and variable association and dissociation kinetic rate constants are going to be used as proof of 
concept.  
 
Figure 1.10 - Schematic representation of new PE-ELISA approach. 
1.4 Aims of the Project 
Although phage display-based enrichments became a standard procedure, they still suffer from 
some drawbacks. To overcome these drawbacks this thesis was initiated with the purpose of 
changing a phage display vector so that one round of selection will be enough, while the affinity 
of all antigen-positive Nbs can be compared immediately after ELISA. More specifically, the 
main goals of the study are: 
• Create a new vector containing the CBP tag that can be used for phage display 
• Immobilize CaM on wells and test the effectiveness and efficiency of the interaction be-
tween the CBP and the CaM with different buffers, concentrations and incubation times 
• Develop a new phage display approach to normalize the amount of expressed Nb before 
ELISA 
• Find the correlation between the ELISA signal and the antigen-binding parameters. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Buffers, Reagents and Culture Media 
Table 2.1 - List of all the buffers, reagents and media used throughout the experiments. 
Buffer/Media/ 
Reagent 
Composition Source City, Country 
1% Agarose Gel 
4 g Agarose 
400 mL TBE buffer 
Boil until agarose dissolves 
Lonza 
 
 
Basel, Switzerland 
 
 
10x TBE Buffer 
(1 L) 
108 g Trizma®Base 
55 g H3BO3 
93 g EDTA 
Adjust final volume to 1 L with 
milli-Q H2O 
Sigma Aldrich 
Sigma Aldrich 
Duchefa Biochemie 
 
 
St. Louis, USA 
St. Louis, USA 
Haarlem, Netherlands 
 
 
20% D-Glucose 
(100 mL) 
20 g Glucose 
Adjust final volume to 100 mL with 
milli-Q H2O 
Autoclave 
Duchefa Biochemie 
 
 
 
Haarlem, Netherlands 
 
 
 
20% Ethanol SEC 
(1 L) 
200 mL Ethanol 
Adjust final volume to 1 L with 
milli-Q H2O 
Filter and degas 
Fisher Scientific 
 
 
 
Loughborough, UK 
 
 
 
20x MES Buffer 
(1 L) 
195.2 g MES Hydrate 
121.2 g Trizma®Base 
20.0 g SDS 
7.44 g EDTA disodium dihydrate 
Adjust final volume to 1 L with 
milli-Q H2O 
Sigma Aldrich 
Sigma Aldrich 
Duchefa Biochemie 
Duchefa Biochemie 
 
 
 
St. Louis, USA 
St. Louis, USA 
Haarlem, Netherlands 
Haarlem, Netherlands 
 
 
 
2x TY Medium 
(1 L) 
16 g Tryptone 
10 g Yeast Extract 
5 g NaCl 
Adjust final volume to 1 L with 
milli-Q H2O 
Autoclave 
Duchefa Biochemie 
Duchefa Biochemie 
Fischer Scientific 
 
 
 
Haarlem, Netherlands 
Haarlem, Netherlands 
Loughborough, UK 
 
 
 
Ampicillin  
(100 mg/mL) 
5 g Ampicillin 
50 mL 70% Ethanol 
Filter with 0.22 µm filter 
Sigma Aldrich 
Fischer Scientific 
Orange Scientific 
St. Louis, USA 
Loughborough, UK 
Braine-l’Alleud, Belgium 
Chloramphenicol 
(25 mg/mL) 
1.25 g Chloramphenicol 
50 mL 100% Ethanol 
Filter with 0.22 µm filter 
Sigma Aldrich 
Fischer Scientific 
Orange Scientific 
St. Louis, USA 
Loughborough, UK 
Braine-l’Alleud, Belgium 
Coating Buffer 
pH 8.2 (1 L) 
8.5 mg Na2CO3 
Adjust pH to 8.2 
Adjust final volume to 1 L with 
milli-Q H2O 
Merck 
 
 
 
Darmstadt, Germany 
 
 
 
Coomassie Bril-
liant Blue  
(1 L) 
0.125 g Coomassie® Brilliant Blue 
R250 
50% Methanol 
10% Acetic Acid 
Adjust final volume to 1 L with 
milli-Q H2O 
Fluka 
 
Acros Organics 
Merk 
 
 
Buchs, Switzerland 
 
Geel, Belgium 
Darmstadt, Germany 
 
 
Destaining Solu-
tion (1 L) 
10% Acetic Acid 
40% Methanol 
Adjust final volume to 1 L with 
milli-Q H2O 
Merck 
Acros Organics 
 
 
Darmstadt, Germany 
Geel, Belgium 
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Buffer/Media/ 
Reagent 
Composition Source City, Country 
Ethidium Bro-
mide (10 mg/mL) 
1 g Ethidium Bromide 
100 mL of milli-Q H2O 
Merck 
 
Darmstadt, Germany 
 
HisPureTM Ni-
NTA Resin 
- 
Pierce (Thermo Sci-
entific) 
Rockford, USA 
Imidazole 0.5M in 
PBS pH 7.5 (100 
mL) 
3.4 g Imidazole 
Solubilize in 90 mL PBS 
Adjust pH to 7.5 
Adjust final volume to 100 mL with 
PBS 
Store in the dark 
Sigma Aldrich 
 
 
 
 
 
St. Louis, USA 
 
 
 
 
 
IPTG 1 M  
(50 mL) 
11.92 g IPTG 
50 mL milli-Q H2O 
Filter with 0.22 µm filter 
Duchefa Biochemie 
 
Orange Scientific 
Haarlem, Netherlands 
 
Braine-l’Alleud, Belgium 
Kanamycin  
(70 mg/mL) 
3.5 g Kanamycin 
50 mL milli-Q H2O 
Filter with 0.22 µm filter 
Duchefa Biochemie 
 
Orange Scientific 
Haarlem, Netherlands 
 
Braine-l’Alleud, Belgium 
LB Agar 
Amp/Chl/Glu  
(1 L) 
25 g LB Broth high salt 
15 g Micro Agar 
Adjust final volume to 900 mL with 
milli-Q H2O 
Autoclave 
1 mL Ampicillin (100 mg/mL) 
1 mL Chloramphenicol (25 mg/mL) 
100 mL 20% Glucose 
Duchefa Biochemie 
Duchefa Biochemie 
 
 
 
 
 
 
Haarlem, Netherlands 
Haarlem, Netherlands 
 
 
 
 
 
 
LB Agar 
Amp/Glu (1 L) 
25 g LB Broth high salt 
15 g micro agar 
Adjust final volume to 900 mL with 
milli-Q H2O 
Autoclave 
1 mL Ampicillin 100 mg/mL 
100 mL 20% Glucose 
Duchefa Biochemie 
Duchefa Biochemie 
 
 
 
 
 
Haarlem, Netherlands 
Haarlem, Netherlands 
 
 
 
 
 
LB Medium  
(1 L) 
10 g Tryptone 
5 g Yeast Extract 
10 g NaCl 
Adjust final volume to 1 L with 
milli-Q H2O 
Autoclave 
Duchefa Biochemie 
Duchefa Biochemie 
Fischer Scientific 
 
 
 
Haarlem, Netherlands 
Haarlem, Netherlands 
Loughborough, UK 
 
 
 
MgCl2 (2 M) 
20.33 g MgCl2 
Adjust final volume to 50 mL with 
milli-Q H2O 
Autoclave 
Merck 
 
 
 
Darmstadt, Germany 
 
 
 
NaAc (3 M) 
3.69 g NaAc 
Adjust pH to 5.2 
Adjust final volume to 15 mL with 
milli-Q H2O 
Sigma Aldrich 
 
 
 
St. Louis, USA 
 
 
 
NaOH-NaCl SEC 
(1 M) 
40 g NaOH 
58.44 g NaCl 
Solubilize in 900 mL milli-Q H2O 
5 mL 10% NaN3 
Adjust final volume to 1 L with 
milli-Q H2O 
Filter and degas 
Fischer Scientific 
Fischer Scientific 
 
Duchefa Biochemie 
 
 
 
Loughborough, UK 
Loughborough, UK 
 
Haarlem, Netherlands 
 
 
 
NuPage® LDS 
Sample Buffer 
(4x) 
- Life Technologies California, USA 
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Buffer/Media/ 
Reagent 
Composition Source City, Country 
NuPage® Sample 
RA (10x) - Life Technologies California, USA 
Orange G DNA 
Loading Dye (6x) 
50 mL 100% Glycerol 
0.5% orange G powder 
Adjust final volume to100 mL with 
milli-Q H2O 
Store in the dark 
Duchefa Biochemie 
Sigma Aldrich 
 
 
 
Haarlem, Netherlands 
St. Louis, USA 
 
 
 
PBS pH 7.4 (10x) 
400 g NaCl 
10 g KCl 
90 g Na2HPO4 
12 g NaH2PO4 
Adjust final volume to 5 L with 
milli-Q H2O 
Autoclave 
Fischer Scientific 
Merck 
Merck 
Merck 
 
 
 
Loughborough, UK 
Darmstadt, Germany 
Darmstadt, Germany 
Darmstadt, Germany 
 
 
 
PBS SEC (1 L) 1 L 1x PBS 
Filter and degas 
  
PBS-Milk 2% 
1 g Milk powder 
Adjust final volume to 50 mL with 
PBS 
Nestle 
 
 
Supermarket 
 
 
PBS-Tween 
0.05% 
0.05% Tween-20 
Adjust final volume with PBS 
Sigma Aldrich 
 
St. Louis; USA 
 
PEG-NaCl (1 L) 
20% PEG w/v PEG 6000 
145.28 g NaCl 
Adjust final volume to 1 L with 
milli-Q H2O 
Duchefa Biochemie 
Fischer Scientific 
 
 
Haarlem, Netherlands 
Loughborough, UK 
 
 
TB Medium  
(1 L) 
2.3 g KH2PO4 
16.4 g K2HPO4.3H2O 
12 g Tryptone 
24 g Yeast Extract 
4 mL 100% Glycerol 
Adjust final volume to 1 L with 
milli-Q H2O 
Autoclave 
Merck 
Merck 
Duchefa Biochemie 
Duchefa Biochemie 
Duchefa Biochemie 
 
 
 
Darmstadt, Germany 
Darmstadt, Germany 
Haarlem, Netherlands 
Haarlem, Netherlands 
Haarlem, Netherlands 
 
 
 
TEA pH 10.0 
70 µL TEA 
Adjust final volume to 5 mL with 
milli-Q H2O 
Sigma Aldrich 
 
 
St. Louis, USA 
 
 
TES pH 8.0  
(1 L) 
24.23 g Trizma®Base 
0.15 g EDTA 
171.15 g Sucrose 
Adjust pH to 8 
Adjust final volume to 1 L with 
milli-Q H2O 
Sigma Aldrich 
Merck 
Duchefa Biochemie 
 
 
 
St. Louis, USA 
Darmstadt, Germany 
Haarlem, Netherlands 
 
 
 
TES/4 pH 8.0  
(1 L) 
250 mL TES 
Adjust final volume to 1 L with 
milli-Q H2O 
  
TPA Buffer 
14.63 g NaCl 
1.4 g Trizma®Base 
Adjust pH to 7.5 
Adjust final volume to 500 mL with 
milli-Q H2O 
Fischer Scientific 
Sigma Aldrich 
 
 
 
Loughborough, UK 
St. Louis, USA 
 
 
 
Transfer Buffer 
6 g Trizma®Base 
28.8 g Glycine 
400 mL Methanol 
Adjust final volume to 2 L with 
milli-Q H2O 
Sigma Aldrich 
Sigma Aldrich 
Acros Organics 
 
 
St. Louis, USA 
St. Louis, USA 
Geel, Belgium 
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Buffer/Media/ 
Reagent 
Composition Source City, Country 
Tris-HCl pH 8.0 
(1 M) 
121.14 g Trizma®Base 
Solubilize in 500 mL of milli-Q H2O 
Adjust pH to 8.0 with 37% HCl 
Adjust final volume to 1 L with 
milli-Q H2O 
Sigma Aldrich 
 
Merck 
 
 
St. Louis, USA 
 
Darmstadt, Germany 
 
 
Tris-HCl pH 8.0 
SEC (200 mM) 
200 mL 1 M Tris-HCl pH 8.0 
5 mL 10% NaN3 
Adjust final volume to 1 L with 
milli-Q H2O 
Filter and degas 
 
Duchefa Biochemie 
 
 
 
 
Haarlem, Netherlands 
 
 
 
WB Development 
Solution 
18 mg 4-chloro-1-napthol 
6 mL Methanol 
30 mL PBS 
18 μL H2O2 
Sigma Aldrich 
Acros Organics 
 
Merck 
St. Louis, USA 
Geel, Belgium 
 
Darmstadt, Germany 
2.1.2 Antibodies, Nanobodies and Antigens 
Table 2.2 – List of antibodies, nanobodies and antigens used throughout the experiments. 
Antibodies/Nanobodies/Antigens Source City, Country 
Goat anti-mouse HRP Sigma Aldrich St. Louis, USA 
Mouse anti-HIS tag Serotec Munich, Germany 
Nb SH30 In house Brussels, Belgium 
Nb SH61 In house Brussels, Belgium 
Nb SH67 In house Brussels, Belgium 
Nb SH68 In house Brussels, Belgium 
Nb SH69 In house Brussels, Belgium 
Nb Sm75 In house Brussels, Belgium 
SIRPα Human In house Brussels, Belgium 
SIRPα Mouse In house Brussels, Belgium 
2.1.3 Plasmids 
Table 2.3 – List of plasmids with their main features specified used throughout the experiments. 
Plasmid Main Features Source City, Country See Figure 
pMECS 
• Plac Promotor 
• PelB Leader Signal Sequence 
• Fd GIII 
• HA Tag 
• HIS Tag 
• Ampicillin Resistance 
In house Brussels, Belgium Figure 2.1 
pMECS-GG 
• Plac Promotor 
• PelB Leader Signal Sequence 
• Fd GIII 
• HA Tag 
• HIS Tag 
• Ampicillin Resistance 
• Chloramphenicol Resistance 
• ccdB Gene 
In house Brussels, Belgium Figure 2.2 
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Figure 2.1 – Schematic representation of pMECS vector 45. 
 
Figure 2.2 - Schematic representation of pMECS-GG vector 46. 
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2.1.4 DNA Manipulation Reagents and Sequences 
Table 2.4 – List of all the DNA manipulation reagents used throughout the experiments. 
Reagent Composition Source 
City, 
Country 
10x O Buffer - 
Thermo 
Scientific 
Vilnius, 
Lithuania 
10x T4 DNA 
Ligase Buffer 
- 
Thermo 
Scientific 
Vilnius, 
Lithuania 
5x Colorless 
GoTaq® Reac-
tion Buffer 
- Promega 
Madison, 
USA 
DNase  
(50 µg/mL) 
- 
Sigma  
Aldrich 
St. Louis, 
USA 
dNTPs  
(10 mM) 
dATP, 100 mM 
dCTP, 100 mM 
dGTP, 100 mM 
dCTP, 100 mM 
All diluted 1:10 in dH2O 
Thermo 
Scientific 
Rockford, 
USA 
EcoRI  
(10 U/µL) 
Restriction Site: 5’…G^AATTC…3’ 
      3’…CTTAA^G…5’ 
Thermo 
Scientific 
Rockford, 
USA 
EXO-I  
(20 U/µL) - 
Thermo 
Scientific 
Rockford, 
USA 
FastAP Ther-
mosensitive 
Alkaline Phos-
phatase  
(1 U/µL) 
- 
Thermo 
Scientific 
Rockford, 
USA 
GoTaq® DNA 
Polymerase  
(5 U/µL) 
- Promega 
Madison, 
USA 
NcoI, 10 U/µL 
Restriction Site: 5’…C^CATGG…3’ 
      3’…GGTAC^C…5’ 
Thermo 
Scientific 
Rockford, 
USA 
NotI, 10 U/µL 
Restriction Site: 5’…GC^GGCCGC…3’ 
            3’…CGCCGG^CG…5’ 
Thermo 
Scientific 
Rockford, 
USA 
Primer CBP-
insert 
5’-GCTCTTCCAGCGGCCGCAAGATGGAA 
AAAGGCCTTTATTGCGGTGAGCGCGGC 
GAACCGGTTTAAAAAAATTAGCGGCAG 
CGGTTCCCACCACCATCACCATCACTAG-
3’ 
Sigma 
Aldrich 
St. Louis, 
USA 
Primer GIII 5’-CCACAGACAGCCCTCATAG-3’ 
Sigma 
Aldrich 
St. Louis, 
USA 
Primer M13 
FWD (FP) 
5’-CGCCAGGGTTTTCCCAGTCACGAC-3’ 
Sigma 
Aldrich 
St. Louis, 
USA 
Primer MP57 5’-TTATGCTTCCGGCTCGTATG-3’ 
Sigma 
Aldrich 
St. Louis, 
USA 
T4 DNA Li-
gase (5 U/µL) - 
Thermo 
Scientific 
Rockford, 
USA 
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2.1.5 Kits 
Table 2.5 - List of kits used throughout of the experiments. 
Kit Source City, Country 
GenEluteTM PCR-Clean-Up Sigma Aldrich St. Louis, USA 
GenEluteTM Plasmid Mini-Prep Sigma Aldrich St. Louis, USA 
QIAquick Gel Extraction Kit QIAGEN Hilden, Germany 
2.1.6 Phages 
Table 2.6 - List of phages used throughout the experiments. 
Phage Main Features Source City, Country 
M13KO7 
• Lacks the infectivity domains N1 and N2 of 
pIII 
• Kanamycin resistance 
Invitrogen California, USA 
2.1.7 Bacterial Strains 
Table 2.7 – List of bacterial strains used throughout the experiments. 
Bacterial 
Strain 
Genotype Source City, Country 
TG1 
K12, Δ(lac-pro), supE thil, hsD5/F’traD36, 
laclq, lacZΔM15, proA+B+ 
In House Brussels, Belgium 
WK6 
K12, Δ(lac-proAB), galE, StrA/F’, laclq, 
lacZΔM15, proA+B+ 
In House Brussels, Belgium 
2.1.8 Molecular Weight Markers 
The Smartladder (Eurogentec, Seraing, Belgium) ranging from 200 bp to 10 kbp was used for 
molecular weight (MW) estimation of nucleic acids during 1% agarose gel electrophoresis (Fig-
ure 2.3A). The PageRulerTM Prestained Protein Ladder (Thermo Scientific, Rockford, USA) rang-
ing from 10 kDa to 180 kDa was used in SDS-PAGE analysis (Figure 2.3B). 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 2.3 - Molecular Weight Markers used throughout the experiments. A – Smartladder (200bp–10kbp) and B – 
PageRulerTM Prestained Protein Ladder (10-180kDa). 
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2.2 Methods 
2.2.1 Cloning Strategies 
2.2.1.1 Amplification of pMECS-GG Using CBP-Insert and FP Primers 
The pMECS-GG empty plasmid was amplified using a mutagenic primer (CBP-Insert) with the 
purpose of adding the CBP tag to the amplified fragment. The primer was designed so that it 
contained the CBP tag sequence and an overlapping region in the vector (HA tag). The amplifi-
cation occurred through a polymerase chain reaction (PCR) using the PCR mix (50 μL per reac-
tion) from Table 2.8. Eight reactions were made to ensure that enough material for the subsequent 
steps was produced. 
Table 2.8 – PCR mix used for one reaction for the PCR of pMECS-GG using CBP-Insert and FP primers. 
Reagent Volume (µL) 
Sterile H2O 35.5 
5x Colorless Go Taq® Reaction Buffer 10 
dNTPs (10mM) 1 
CBP-Insert primer (20µM) 1 
RP primer (20µM) 1 
Go Taq® G2 DNA Polymerase (5U/μL) 0.5 
Template 1 
The PCR strips were placed in the Westburg T3 thermo cycler from Biometra® and a PCR pro-
gram started. Since a large fragment should be amplified, the designed program used a longer 
extension step to have sufficient time to synthesize the full-length amplicon. The program con-
tained an initial denaturation step at 95°C for 5 mins, followed by 28 cycles of 45 seconds at 
94°C, 45 seconds at 55°C and 1 min at 72°C, at the end an extension step at 72°C for 10 mins 
was included. 
The amplified product was verified by gel electrophoresis (see section 2.2.1.8) to assess the cor-
rect fragment amplification (around 1300 bp) and was purified with the GenEluteTM PCR Clean-
Up Kit according to the manufacturer’s instructions. 
2.2.1.2 Amplification of Nbs Using MP57 and GIII Primers 
The pMECs plasmids encoding for the SIRPα human Nbs 30, 61, 67, 68, 69 and the SIRPα mouse 
Nb75 (all provided by Ema Romão, Cellular and Molecular Immunology Laboratory, Vrije Uni-
versiteit Brussel) were taken as template for amplification using GIII and MP57 primers. This 
was a way of obtaining a large amount of Nb fragments without using a lot of template. Moreover, 
it assured that after digestion, the majority of the product was the fragment containing the Nbs, 
therefore the purification using the GenEluteTM PCR Clean-Up Kit was enough. Amplification 
via PCR occurred according with Table 2.9. Eight reactions were made to ensure that enough 
material for the subsequent steps was produced. 
 Table 2.9 – PCR mix used for one reaction for the PCR of pMECS containing the Nbs using MP57 and GIII primers. 
Reagent Volume (µL) 
Sterile H2O 35.5 
5x Colorless Go Taq® Reaction Buffer 10 
dNTPs (10mM) 1 
GIII primer (20µM) 1 
MP57 primer (20µM) 1 
Go Taq® G2 DNA Polymerase (5U/μL) 0.5 
Template 1 
The Westburg T3 thermo cycler from Biometra® was used for the PCR reaction. The PCR strips 
containing the PCR reaction were placed in the PCR thermocycler and underwent a denaturation 
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step at 95°C for 3 mins, followed by 28 cycles of 30 seconds at 94°C, 30 seconds at 57°C and 45 
seconds at 72°C, finally an extension step at 72°C for 10 mins was included. 
The amplified products were verified by gel electrophoresis (see section 2.2.1.8) for the correct 
fragment amplification (around 600-800 bp) and were purified with the GenEluteTM PCR Clean-
Up Kit according to the manufacturer’s instructions. 
2.2.1.3 Digestion of Amplification CBP Fragment and pMECS with Not I and EcoRI 
Digestion of amplification fragment: To 5 μg of the CBP amplification fragment, 1 μL NotI (10 
U/μL) and 1 μL EcoRI (10 U/μL) were added. 10x buffer O was also added to the mixture to 
reach a final concentration of 1x and the volume was adjusted with sterile H2O. The digestion 
was performed for 3 h at 37°C. The digested product was purified with the GenEluteTM PCR 
Clean-Up Kit according to the manufacturer’s instructions. 
Digestion of pMECS: To 5 μg of the pMECS vector 1 μL NotI and 1 μL EcoRI were added. 10x 
buffer O was also added to the mixture to obtain a final concentration of 1x and the volume was 
adjusted with sterile H2O. The digestion was performed for 3 h at 37°C. Afterwards, the entire 
reaction volume was loaded on a 1% agarose gel electrophoresis (see section 2.2.1.8). The band 
of digested vector was cut out of the agarose gel and purified with the QIAquick Gel Extraction 
Kit following the manufacturer’s protocol. 
2.2.1.4 Digestion of pMECS-CBP, pMECS-GG, Amplification Nbs Fragments and 
pHEN18 containing SIRPα mouse with NotI and NcoI 
Digestion of pMECS-CBP: To 5 μg of pMECS-CBP, 4 μL NcoI and 1 μL NotI were added. 10x 
buffer O was also added to the mixture to reach a final concentration of 1x and the volume was 
adjusted with sterile H2O. The digestion was performed for 3 h at 37°C. The digested product was 
purified with the GenEluteTM PCR Clean-Up Kit according to the manufacturer’s instructions. 
Digestion of pMECS-GG (to insert Golden Gate): To 5 μg of the pMECS-GG vector 4 μL NcoI 
and 1 μL NotI were added. 10x buffer O was added to the mixture to obtain a final concentration 
of 1x and the volume was adjusted with sterile H2O. The digestion was performed for 3 h at 37°C. 
Afterwards, the entire reaction volume was loaded on a 1% agarose gel electrophoresis (see sec-
tion 2.2.1.8). The band of digested vector was cut out of the agarose gel and purified with the 
QIAquick Gel Extraction Kit following the manufacturer’s protocol. 
Digestion of amplification Nbs fragments: To 5 μg of each Nbs amplification fragments, 4 μL 
NcoI and 1 μL NotI were added. 10x buffer O was also added to the mixture to reach a final 
concentration of 1x and the volume was adjusted with sterile H2O. The digestion was performed 
for 3 h at 37°C. The digested product was purified with the GenEluteTM PCR Clean-Up Kit ac-
cording to the manufacturer’s instructions. 
Digestion of pHEN18 containing SIRPα mouse: To 5 μg of the pHEN18 vector containing SIRPα 
mouse 4 μL NcoI and 1 μL NotI were added. 10x buffer O was also added to the mixture to have 
a final concentration of 1x and the volume was adjusted with sterile H2O. The digestion was 
performed for 3 h at 37°C. Afterwards, the entire reaction volume was loaded on a 1% agarose 
gel electrophoresis (see section 2.2.1.8). The band of digested vector was cut out of the agarose 
gel and purified with the QIAquick Gel Extraction Kit following the manufacturer’s protocol. 
2.2.1.5 Ligation of Fragment to Wanted Vector 
The ligation was performed overnight (O/N) at 16°C with 30 ng of the fragment to insert, 100 ng 
of vector, 1 μL T4 DNA ligase and 2 μL T4 DNA ligase 10x buffer for a total volume of 20 μL. 
The ligation was followed by purification using phenol-chloroform DNA precipitation. Sterile 
H2O (80 μL) was added to the ligation product to make a final volume of 100 μL. Then 100 μL 
of the lower phase of 25:24:1 phenol/chloroform/isoamyl (Sigma Aldrich, St. Louis, USA) was 
added and shaken vigorously before centrifugation (Eppendorf Centrifuge 5417R) at 14000 rpm 
for 5 mins. After centrifugation, the upper phase was transferred to a new Eppendorf tube, 10 μL 
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3 M NaAc pH 5.2 and 250 μL 100% ethanol were added to the ligation product and it was stored 
for at least 1 h at -80°C for DNA precipitation. Next, the ligation product was centrifuged for 30 
mins at 14000 rpm and 4ºC. Subsequently, the ethanol was removed, the pellet was dried on the 
heat block (Thermolyne type 16500 Dri Bath) and resuspended in 5 μL of sterile H2O. 
The ligations were made between: amplificon of CBP fragment and pMECS, Golden Gate and 
pMECS-CBP, amplificon of Nb fragments and pMECS-CBP, as well as SIRPα mouse and 
pMECS-CBP. 
2.2.1.6 Plasmid Transformation in Electrocompetent Bacterial Cells 
Transformation of the plasmids in bacterial host cells was required to perform a colony PCR and 
DNA sequencing for identification of correct constructs. The bacterial cells needed to be made 
competent so that they were capable to take up extracellular DNA from their surroundings. WK6 
E. coli cells were made electrocompetent (ECC) as described in 45. 
The plasmid transformation was carried out by mixing 50 μL ECC with 2 μL of ligation product, 
followed by an incubation on ice for 5 mins. After setting the electroporation apparatus E. coli 
Pulser® (Bio-Rad Laboratories, Hercules, California, USA), the cells were loaded into an electro-
poration cuvette (Bio-Rad Laboratories, Hercules, California, USA). Then, the cuvette was placed 
into the electroporation chamber and a pulse of 1.8 kV was applied. The cuvette was removed 
and 500 µL of LB was immediately added and transferred to an Eppendorf tube. The cuvette was 
rinsed with another 500 µL of LB, that were pooled to the same Eppendorf. The cell suspension 
was incubated at 37ºC for 1h on a shaker (200 rpm). 100 μL of the obtained culture were plated 
on a round LB Agar. The remaining culture was centrifuged for 3 mins at 2000 rpm. The pellet 
was also plated on fresh LB agar and the plates were incubated O/N at 37°C. On vectors where 
the Golden Gate killer cassette was present, the LB agar plates used were Amp/Chl/Glu, while on 
the other vectors the plates were only supplemented with Amp/Glu. 
2.2.1.7 Colony PCR and DNA Sequencing 
For screening of the new vectors created after transformation, some isolated colonies were picked 
from the round LB agar Amp/Glu plate or LB agar Amp/Chl/Glu (depending on the vector used) 
with a sterile tip, scratched on a new LB agar plate and submerged in the PCR mix (Table 2.10) 
in the well of the PCR strip. After the colonies were marked on the LB agar plate, the plate was 
incubated O/N at 37°C and stored at 4°C subsequently. 
Table 2.10 - PCR mix used for one reaction of colony PCR 
Reagent Volume (µL) 
Sterile H2O 37.25 
5x Colorless Go Taq® Reaction Buffer 10 
dNTPs (10mM) 0.5 
GIII primer (20µM) 1 
MP57 primer (20µM) 1 
Go Taq® G2 DNA Polymerase (5U/μL) 0.25 
The PCR strips were placed in the Westburg T3 thermo cycler from Biometra® and a PCR pro-
gram started. Since the introduction of the Golden Gate generated a large fragment (around 1500 
bp) between the primers, the program comprised an initial denaturation step at 95°C for 5 mins, 
followed by 28 cycles of 45 seconds at 94°C, 45 seconds at 55°C and 1 min at 72°C, a final 
extension step at 72°C for 10 mins was performed. For the other constructs, the fragment between 
MP57 and GIII primers was around 400-800 bp, so there was no need for the program to include 
a long elongation step. The program was an initial denaturation step at 95°C for 3 mins, followed 
by 28 cycles of 30 seconds at 94°C, 30 seconds at 55°C and 45 seconds at 72°C, a final extension 
step at 72°C for 10 mins was performed. 
Next, the amplicons were verified by gel electrophoresis (see section 2.2.1.8). Constructs with 
the right size, depending on the construct (sequence length between MP57 and GIII primers), 
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were selected and purified with the ExoSAP procedure. 1.5 μL of the selected constructs were 
treated with 0.2 μL of ExoI (20 U/μL) and 0.4 μL of FastAP (1 U/μL), 12.9 μL of sterile H2O was 
added as well. The primers and dNTPs degradation occurred by activation of the enzymes at 37°C 
for 15 mins, followed by an immediate inactivation at 80°C for another 15 mins.  
To the cleaned PCR products was added 2 μL of MP57 primer (10 μM) and it was sent for DNA 
sequencing at Eurofins Genomics. The resulting sequences were analyzed with CLC Main Work-
bench 7.9.1 software (CLC Bio, Qiagen Bioinformatics). 
Using a construct with the correct insertion by picking the corresponding colony from the LB 
agar plate mentioned before, a preculture of 5 mL supplemented with 1/1000 ampicillin stock was 
made and incubated O/N at 37ºC and 200 rpm. The preculture was used for plasmid extraction 
with the GenEluteTM Plasmid Mini-Prep kit according to the manufacturer’s instructions. The 
purified plasmids were sequenced again for confirmation of the sequences and stored at -20ºC. 
2.2.1.8 Agarose gel Electrophoresis 
A 1% agarose gel solution was poured in a gel frame with a well frame and ethidium bromide 
(0.5 μg/mL) was added and stirred into the gel solution. The gel was solidified for at least 30 mins 
and then immersed in a tank (Bio-rad Mini-Sub® Cell GT, Bio-Rad Laboratories, Hercules, Cal-
ifornia, USA) filled with 1x TBE. 10 μL of each sample was supplemented with 2 μL of orange 
G DNA loading dye 6x and loaded into the wells of the gel. A 5 μL aliquot of the Smartladder 
MW ladder (Eurogentec, Seraing, Belgium) was also loaded into in one of the wells. The gel was 
connected to an EC250-90 Electrophoresis Power Supply (E-C Apparatus Corporation) at 115 V 
for 35 mins. After running, the gels were then visualized on a Vilber Lourmat UV transilluminator 
(Germany) and photographed with CCD video camera (Rainbow CCTV RMB92) connected to 
Mitsubishi P91 printer (Mitsubishi electric). 
2.2.2 Phage Display of Nanobodies 
2.2.2.1 Preparation of the Libraries 
The purpose of this phage display was not to select Nbs of highest affinity, but rather understand 
if the new vector created with the CBP was suitable for this technique. For that reason, the mini-
library made was a little bit different, since it was already known that the Nbs used were binders 
of human SIRPα. 
For the creation of these libraries, 100 ng of vectors pMECS and pMECS-CBP containing the 
Nbs were inserted into TG1 E. coli cells, by transformation via electroporation (see section 
2.2.1.6). TG1 E. coli cells were made ECC as described in 45. Instead of plating the cell suspen-
sions, these were inoculated into 300 mL 2x TY supplemented with 1/1000 dilution Ampicillin 
stock (100 mg/mL) and 15 mL glucose stock (20%). Two bottles were used, one had all 6 Nbs 
without any modification, while the other had all Nb with the CBP tag. The bottles were incubated 
on a shaker (220 rpm) at 37°C O/N to allow the phagemid vector to grow and were used as 
precultures.  
Two mini libraries comprising the 6 Nbs each were created: “Nbs against SIRPα” and “Nbs-CBP 
against SIRPα”. 
2.2.2.2 Inoculation of the Libraries 
Medium of 300 mL 2xTY supplemented with 1/1000 dilution Ampicillin stock was prepared, 
allowing only TG1 E. coli cells containing the phagemid vector to grow. Also, 15 mL glucose 
stock was added to suppress the LacZ promoter, thus preventing leaky expression of the Nb pro-
tein, since this could interfere with the infection of TG1 E. coli cells with bacteriophages. The 
medium was inoculated with a 1 mL aliquot of TG1 E. coli cells from the mini libraries “Nbs 
against SIRPα” and “Nbs-CBP against SIRPα” (from section 2.2.2.1), which had been growing 
O/N (therefore in stationary phase). The bottles were incubated on a shaker (250 rpm) at 37°C 
until the OD600nm reached 0.6-0.8 (usually 2-3h), meaning they had reached the exponential 
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growth phase. Following, approximately 1012 M13KO7 helper phages preserved in glycerol were 
added and incubated at 37°C without shaking for 30 mins to allow the phages to attach to the F-
pilus of E. coli. The cells were centrifuged in 50 mL tubes for 10 mins at 2700 rpm and the 
supernatant was removed. The cell pellets were resuspended in 300 mL 2xTY supplemented with 
1/1000 dilution of Ampicillin stock and 1/1000 dilution of Kanamycin stock (70 mg/mL). Incu-
bation O/N at 37°C on a shaker (225 rpm)  allowed the production of recombinant phages con-
taining a Nb at their tip. 
2.2.2.3 Preparations for Panning 
To prepare for panning, a single well of a Nunc Maxisorp ELISA 96-well plate (Thermo Scien-
tific, Denmark) was coated with 10 μg of SIRPα human in 100 μL of Coating Buffer pH 8.2 and 
stored at 4°C O/N. TG1 E. coli cells were plated on a LB Agar Amp/Glu plate and incubated O/N 
at 37°C so that a single colonies grown could be used to make a preculture for further steps. 
2.2.2.4 Panning 
Phage preparation: 300 mL O/N bacterial culture infected with M13KO7 helper phage (from sec-
tion 2.2.2.2) were centrifuged for 30 mins at 8000 rpm and 8°C. Following, 40 mL supernatant 
was added to 10 mL PEG/NaCl (20%) until all the supernatant was in contact with the PEG/NaCl 
solution. After inverting the tubes several times, these were kept on ice for 30 mins and, subse-
quently, centrifuged for 30 mins at 4000 rpm and at 4°C. The supernatant was discarded and the 
pellet containing the phages was resuspended in 1 mL sterile PBS. The solution was centrifuged 
for 2 mins at 14000 rpm and the supernatant was collected. The OD260nm was measured so that 
approximately 1011 phages per well were added, taking into account that OD260nm of 1 = 3x1010 
particles/mL 
ELISA-plate preparation: Non-bound antigen of the 96-well plate (from section 2.2.2.3) was re-
moved by inverting the plate. The plate was washed 5x with PBS-Tween (PBST) and the positive 
well (with antigen), as well as an empty well (negative control), were blocked with 200 μL of 
PBS-Milk blocking buffer for at least 1h. After the blocked wells have been washed 5x with 
PBST, 100 μL of phages was added to both wells, followed by incubation of at least 1h at room 
temperature (RT), to allow the Nb-displayed phages to recognize and bind to the coated antigen. 
Next, the wells were washed 20x with PBST and the bound phages were eluted after 10 mins of 
addition of 100 μL TEA solution. Finally, the solution with the phages was transferred into an 
Eppendorf tube that contained 100 μL Tris-HCl 1 M pH 8.0 to neutralize the solution. All proce-
dures were performed on the positive and negative control wells. 
TG1 preculture preparation: At the same time of phage preparation, TG1 colonies were inoculated 
onto 5 mL LB medium to make a preculture and onto a second 5 mL LB medium to which 1/1000 
dilution of Ampicillin stock was added, with the purpose of having a negative control. This was 
incubated at 37°C on a shaker (200 rpm) until the cells reached the exponential growth phase.  
2.2.2.5 Visualization of Enrichment Factor 
Two columns (positive and negative) of a 96 round-bottom-well plate (Corning Incorporated, 
New York, USA) were filled with 90 μL of sterile PBS in each well and two additional columns 
were filled with 90 μL TG1 cells of the preculture (from section 2.2.2.4). Next, 10 μL of the 
positive phages (from section 2.2.2.4) were diluted by transferring them to the first well of the 
PBS column, mixing and adding to the second well, generating a 1/10 serial dilution but leaving 
the last row as control, meaning without phages.10 μL of all these dilutions was transferred to the 
corresponding wells of the column with TG1 cells. The same procedure was performed to the 
negative phages in different columns of the plate. 
After an incubation for 30 mins up to 1 h that allowed the phages to infect the TG1 cells, 10 μL 
of each well were transferred onto a square LB Agar Amp/Glu and the suspension was spread to 
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obtain two columns of serial dilutions, a positive and a negative control. After an O/N incubation 
at 37°C, the enrichment was determined. 
Enrichment is a representation of the chance to find better Nb binders and can be calculated by 
counting the colonies of the positive and negative lines where single colonies can be seen and 
then dividing the number of positive colonies by the number of negative colonies, considering the 
dilution factor where they can be seen. The larger this enrichment factor, the higher the chances 
for finding better binders. 
2.2.3 Periplasmic Expression and Purification of Nanobodies and 
SIRPα mouse 
The expression of the Nbs and Ag (SIRPα mouse) containing or not the CBP tag was done to 
understand if there was a problem of expression with any of the constructs. All of the procedures 
mentioned bellow were based on 45.  
2.2.3.1 Transformation into Electrocompetent WK6 E. coli Cells 
For production and purification of Nbs, the vector containing the Nb-insert was introduced into 
WK6 E. coli cells. These cells are a non-suppressor strain that can not to read through the vector’s 
amber stop codon between gene III and the Nb-insert. This will allow the Nb expression as a 
soluble protein in the periplasm of the bacterial cells.  
The introduction of the vectors containing the Nb or Ag into the ECC WK6 E. coli cells was 
performed through an electroshock, as described in section 2.2.1.6., but instead of 2 μL of plas-
mid, 100 ng were added. 
2.2.3.2 Precultures of WK6 E. coli 
To prepare for Nb expression, a WK6 colony containing the Nb or Ag of interest with and without 
the CBP tag was used to inoculate 5 mL LB medium supplemented with 1/1000 dilution of Am-
picillin stock. This was done three times for each clone to obtain a final volume of 15 mL inocu-
lated medium and ensure that in the next day there was material to proceed. After an O/N incu-
bation at 37°C on a shaker (200 rpm), the precultures of the same clone that shown turbidity were 
pooled and used for inoculation. Also, 5 mL of this preculture was used for plasmid extraction by 
GenEluteTM Plasmid Mini-prep kit. This was sent for sequencing to Eurofins Genomics to confirm 
the cloned Nb/Ag insert. 
2.2.3.3 Expression in WK6 E. coli 
To obtain 1 L of WK6 culture, three baffled shaker flasks containing 330 mL TB medium sup-
plemented with 1/1000 Ampicillin stock and 1.5 mL glucose stock. Each flask was also inoculated 
with 2 mL preculture (from section 2.2.3.2). This was incubated at 37°C on a shaker (220 rpm) 
for 2-3 h until the OD600nm reached 0.6-0.9, which meant that the cells have reached the exponen-
tial growth phase. Then, 1 mM IPTG was added to induce the periplasmic expression of the Nbs 
or Ag and the flasks were incubated O/N at 28°C on a shaker (220 rpm). 
2.2.3.4 Periplasmic Extraction 
The next day, the Nbs or Ag were extracted from the periplasm of WK6 cells via osmotic shock. 
The first flasks of each O/N culture were centrifuged for 8 mins at 8000 rpm. The supernatant 
was discarded, and this was repeated for the other two flasks whereby the same centrifugation 
bottle was used per clone in order to obtain one pooled pellet of 1L of media (three pellets). The 
pellet was dissolved in 12 mL TES and the bottles were incubated for 1 h at 4°C on a shaker (200 
rpm). Subsequently, 24 mL TES/4 was added to each bottle to create an osmotic shock, which 
caused the Nbs and other proteins from the periplasm to exit the cells. When the lysozyme was 
added to enhance the periplasmic extraction, 300 µL of 2 M MgCl2, DNase (50 µg/mL) and Ly-
sozyme (5 mg/mL) were also added to each bottle. The bottles were further incubated for 2 h at 
4°C on a shaker (200 rpm) and centrifuged for 30 mins at 8000 rpm. The supernatant, which 
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contained the Nbs, was collected in 50 mL tubes and stored at 4°C. The periplasmic extraction 
was repeated to maximize the yield from each pellet by dissolving it again in TES and doing an 
osmotic shock with TES/4, however this time the incubation was performed for 4 h and O/N. 
Again, when the lysozyme was added to enhance the periplasmic extraction, it was on the step of 
the TES/4, adding 300 mL of 2 M MgCl2, DNase (50 µg/mL) and Lysozyme (5 mg/mL), as well. 
The next day, a centrifugation for 30 mins at 8000 rpm was done and the supernatant was col-
lected. 
2.2.3.5 First Purification Step: IMAC 
Immobilized metal affinity chromatography (IMAC) is a purification method that isolates pro-
teins containing a His tag based on the high affinity binding of histidine to metal ions, such as 
nickel. The Ni-beads needed to be washed, by using 1 mL of HisPure Ni-NTATM Resin suspension 
per liter of culture and adding PBS to a final volume of 50 mL. This was centrifuged for 7 mins 
at 1400 rpm and the excess of PBS was discarded. Subsequently, 500 μL of the washed Ni-beads 
suspension was added to each 50 mL tube containing the periplasmic extracts (section 2.2.3.4) 
and the tubes were incubated for 1 h at RT on a shaker (100 rpm) to allow binding of the Nbs to 
the Ni-beads. The suspension was poured into a PD-10 column (GE Healthcare Life Sciences) 
containing a filter to retain the Ni-beads conjugated with the Nbs and allow the periplasmic extract 
to flow through. The tubes were rinsed with 50 mL PBS and then the solution was also added into 
the column. When the solution had flown through, the column was sealed, and 1 mL of 0.5 M 
Imidazole in PBS was added to elute the Nbs. Since, imidazole is identical to the R group of 
Histidine, it will be a competitive binder for Nickel beads. Nevertheless, it is used in such a high 
concentration that it causes the His tagged Nbs to elute. After 10 mins of incubation with imidaz-
ole in PBS, the flow through containing the Nbs was collected into Eppendorf tubes. This step 
was repeated 5 times to obtain 5 Eppendorf tubes of 1 mL eluted IMAC containing the Nb. The 
protein concentration of each tube was measured in the Nanodrop spectrophotometer (Isogen Life 
Sciences ND 1000) at OD280nm considering the theoretical extinction coefficient of each Nb/Ag, 
calculated by the ProtParam tool (http://www.expasy.ch/tools/protparam.html). Next, the frac-
tions with concentration higher than 0.1 mg/mL were pooled. In the cases where the total concen-
tration of the 5 fractions was lower than 1 mg/mL, all the fractions were pulled and concentrated. 
In the cases a concentration of the fractions was needed, the pulled fraction was loaded into a 
Vivaspin 5000 MW HY (Vivascience – Sartorius) and centrifuged at 2000 g for 20 mins or until 
reaching the final volume of 500 µL. 
2.2.3.6 Second Purification Step: SEC 
To further purify the Nbs, size exclusion chromatography (SEC) was done using fast protein liq-
uid chromatography (FPLC), thus the separation was done according to their molecular weight 
(MW). The samples collected from IMAC (section 2.2.3.5) were loaded onto a Superdex 75 col-
umn (16/600) on AktaXpress or a Superdex 75 column (10/300) on AktaXplorer10S (all from GE 
Healthcare) depending on the concentration of the samples. The column was equilibrated with 
PBS, which was also the running buffer. The run was carried out following standard operating 
procedures present in the lab. The OD280nm was measured during the run to determine which of 
the eluted fractions contained the Nb protein and needed to be pooled. The concentration of these 
pooled protein fractions was measured in the Nanodrop spectrophotometer (Isogen Life Sciences 
ND 1000) at OD280nm considering the extinction coefficient of each Nb/Ag, to calculate the final 
yield of purified Nb. 
Between two SEC runs, the column was decontaminated with one column volume of NaOH-NaCl 
(1 M) SEC buffer, neutralized with two volumes of Tris-HCl (200 mM) SEC buffer, maintained 
in one volume of 20% ethanol SEC buffer and equilibrated for the next run with one volume of 
PBS SEC buffer. 
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2.2.3.7 SDS-PAGE 
To check the purity/presence of the obtained Nbs/Ag, a sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed. Therefore, 5 μg of Nb protein and of a positive 
control (SIRPα human) were mixed with 4x NuPAGE® LDS Sample Buffer and 10x NuPAGE® 
Sample Reducing Agent. Additionally, several aliquots were taken during the crucial steps of 
production and purification to evaluate the enrichment. In this case, the aliquots that could have 
been directly quantified, 5 μg were added, for the samples that couldn’t, 13 μL were added. The 
samples were heated in a heat block for 10 mins at 100°C. Subsequently, a 12 % NuPAGE® Bis-
Tris polyacrylamide gel was placed in a Bio-Rad X-cell SureLockTM SDS-PAGE tank that was 
filled with 300 mL of 1x MES buffer. The samples were loaded onto the gel along with 5 μL of 
the PageRulerTM Prestained Protein Ladder to determine the MW of the samples. The gel was run 
at 115 V for at least 1 h to allow the migration of the proteins. Next, it was stained with Coomassie 
Blue staining solution and placed on a shaker for 1 h to allow coloring of the proteins in the gel. 
Finally, a destaining solution was added for at least 3 h while shaking to allow visualization of 
the proteins. 
2.2.3.8 Western Blot 
For the western blot, the polyacrylamide gel electrophoresis was done the same way as described 
for the SDS-PAGE (section 2.2.3.7). After obtaining the gel with the separated proteins, it was 
transferred onto a nitrocellulose blotting membrane (Amersham Protran 0.45 NC, GE Healthcare) 
and placed into a western blot holder (BioRAD mini protean® II cell) that contained transfer buffer 
and an ice block to reduce the heating during transfer. The transfer of the proteins within the gel 
to the membrane was run for 1 h at 100 V. Afterwards, the membrane that contained the trans-
ferred proteins needed to be developed the same way as an ELISA. Briefly, protein binding sites 
on the membrane were blocked with PBS-Milk for at least 1 h while shaking, washed three times 
with PBS, incubated for at least 1 h with a 1/2000 dilution of α-HIS mAb in PBS while shaking, 
washed again three times, incubated for at least 1 h with a 1/2000 dilution of α-Mouse IgG - HRP 
conjugate in PBS, while shaking, and washed three times. The proteins were visualized by addi-
tion of the western blot developing solution and incubation of the membrane for 5-10 mins in the 
dark. The reaction was stopped and rinsed with distilled water. 
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3 Results and Discussion 
3.1 Design of new Vector 
This project started with the substitution of the Hemagglutinin (HA) peptide detection tag down-
stream of the Nb cloning site from pMECS-GG phage display vector with a new CBP tag using 
a mutagenic primer (CBP-Insert). While designing the cloning strategy, it became clear that this 
could not be done in only one step. First, the CBP tag had to be cloned into the original pMECS 
vector. This was achieved by amplifying via PCR a pMECS-GG fragment, using CBP-insert and 
FP as primers. Then, the amplified fragment and pMECS vector were digested using EcoRI and 
NotI and, after purification, these fragments were ligated to obtain the vector pMECS-CBP. This 
construct was then transformed into a non-suppressor WK6 E. coli strain. Fourteen bacterial col-
onies were picked to perform a PCR in order to check which of these contained the CBP insert 
(Figure 3.1). Analysis of the 1% agarose gel, it seems that not all the colonies had the right insert. 
Considering that the only difference between the two vectors is the CBP (a 19 aa peptide), the 
apparent MW is only marginally different. However, it is still possible to see which colonies have 
the correct insert. For example, the samples 5 and 12 have the pMECS-CBP vector, while the 
samples 7 and 13 had the self-ligated vector (pMECS). Two or three plasmids with putative cor-
rect inserts were sent for sequencing to guarantee that the correct vector was selected, followed 
by plasmid preparation using the putative correct colonies. 
 
Figure 3.1 – 1% agarose gel after colony PCR with primers MP57 and GIII to examine which have the CBP insert. 
The first lane contains the DNA SmartLadder. 1-14 Randomly selected WK6 E. coli colonies. 
A re-cloning of the Golden Gate killer cassette was performed to pMECS-CBP. The restriction 
enzymes used for this re-cloning were NotI and NcoI. After digestion, a gel extraction to purify 
the fragment containing the Golden Gate killer cassette was necessary. Since the fragment wanted 
for the ligation was the smaller (1500 bp), purification only by PCR CleanUp Kit wouldn’t re-
move the larger digested fragment and, consequently, it would promote self-ligation 47, leaving 
less amplicon available for the wanted ligation. For a better understanding of what is happening 
during cloning, a digestion profile can be performed (Figure 3.2). The profile reviews all steps of 
digestion, including before and after purification steps to ensure that fragments used in ligation 
are pure. Analyzing the contents within lanes 6 and 7 (Figure 3.2), it is observed that the 1500 bp 
fragment was indeed purified, since the larger fragment disappeared. Most of the times, when a 
larger fragment disappears is due to gel extraction. A way of understanding if the restriction en-
zymes are efficient is comparing the digested product with the undigested plasmid (lanes 2 and 
3, for example). An undigested plasmid is characterized by three bands on agarose gel that corre-
spond to three different isoforms (supercoiled, linear and open circular) 48. The electrophoretic 
migration is dependent on size and conformation, due to differences in hydrodynamic interactions 
and degree of chain entanglement 48 49. Thus, the supercoiled conformation is the one that migrates 
faster, since there are less conformational restrictions, followed by linear conformation and being 
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open circular the one that migrates less 48. Analyzing the contents of lanes 2, 5 and 9 it is observed 
that all isoforms mentioned previously were present in all pure plasmids. If after digestion, a 
similar result to undigested plasmid is obtained, a problem occurred, and a new digestion must be 
done. Since all digestion steps seemed acceptable, a ligation was done followed by transformation 
in bacterial cells for colony PCR with MP57 and GIII as primers. Fourteen bacterial colonies were  
picked to check which had the vector pMECS-GG-CBP (Figure 3.3). 
Insertion of Golden Gate killer cassette was expected to be around 1500 bp (lane 3, for example), 
while pMECS-CBP self-ligation was expected to be around 400 bp (lane 8, for example). Se-
quencing confirmed the construction of the correct vector and plasmids were prepared using the 
correspondent colonies. 
 
Figure 3.3 – 1% agarose gel after colony PCR with primers MP57 and GIII to examine which have the Golden Gate 
insert. The first lane is the DNA SmartLadder. 1-14 Randomly selected WK6 E. coli colonies. 
Also, 6 Nbs with well-established and different association and dissociation kinetic rate constants 
(provided by Ema Romão) were inserted in the vector pMECS-CBP. NotI and NcoI were the 
restriction enzymes used for digestion, and, after ligation, the vectors were transformed in WK6 
E. coli and colony PCR with primers MP57 and GIII was, once more, used to discover the colonies 
Figure 3.2 – A – DNA SmartLadder used as a marker for the size of the bands (expressed in bp). B – 1% agarose gel 
of digestion profile of re-cloning Golden Gate killer cassette into pMECS-CBP. 1 – DNA SmartLadder. 2 – Undi-
gested pMECS-CBP. 3 – Digested pMECS-CBP with NotI and NcoI, not purified. 4 - Digested pMECS-CBP with 
NotI and NcoI, purified. 5 – Undigested pMECS-GG. 6 - Digested pMECS-GG with NotI and NcoI, not purified. 7 - 
Digested pMECS-CBP with NotI and NcoI, purified. 8 – ligation product pMECS-GG-CBP. 
A B 
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with the right constructs (Figure 3.4). Vectors with Nbs genes had amplification fragments around 
600 bp and were sent for sequencing. Plasmids for each Nb were prepared to be used in further 
experiments.  
 
Figure 3.4 - 1% agarose gel after colony PCR with primers MP57 and GIII to examine which have the Nb30 insert. 
The first lane is the DNA SmartLadder. 1-14 Randomly selected WK6 E. coli colonies.  
Sequences of all vectors created were analyzed using CLC Main Workbench 7.9.1 software, to 
guarantee not only the right insertions, but also that all key elements were functional. Figure 3.5 
summarizes all modifications made to pMECS, to transform it into all forms of pMECS-CBP, 
with the red region being a variable sequence depending on the Nb/Golden Gate that were in-
serted. The vector was designed either for phage display or periplasmic expression of the Nb 
encoded 45. The lac promoter/operator is inducible by IPTG and repressed by glucose 50. The 
periplasmic transport is provoked by the N-terminal signal peptide pelB, which enables transport 
through the inner membrane of bacteria 51. In each Nb there is a CDR3 encoded, which defines a 
Nb family 52. Due to deriving from the same B-cell lineage, Nbs from the same family bind to the 
same epitope on the target 52. The His tag allow  simultaneously immunodetection and purification 
via IMAC 53. All these elements can be seen on the vectors created (Figure 3.5), along with the 
inserted CBP domain, which might indicate that the expression of the Nb-CBP could occur. 
 
Figure 3.5 - Schematic representation of all modifications made to pMECS to create all pMECS-CBP vectors. 
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3.2 Phage Display of Nanobodies 
After obtaining the new phage display vector, two mini libraries were created to test the effec-
tiveness of the construct on phage display.  
Since the goal wasn’t to isolate the Nbs of highest affinity, but rather understand if the new vector 
was suitable for phage display, a different approach was used. The mini libraries created included 
6 Nbs that were already selected in the lab against human SIRPα and the difference between them 
was the vector used. One library was generated in the pMECS vector, producing the original Nbs 
discovered by phage display. Thus, even with just one round of panning it was expected that an 
enrichment occurred. The other library was generated in the new pMECS-CBP vector, to evaluate 
if a similar enrichment could be achieved. Moreover, the libraries were created by simply trans-
forming the same amount of each Nb in TG1 cells (which suppress the amber stop codon 54), 
using electroporation and then allowing all the cells to grow O/N while shaking. The next day, 
these precultures were used for library inoculation and the cells were infected with M13 helper 
phages. The next day the phages were purified, and a single round of panning was performed. A 
comparison between to libraries was done by observing the enrichment on LB Agar Amp/Glu 
pates (Figure 3.6). 
The library in pMECS showed an enrichment by a factor of 1000 or more, whereas the mini 
library in pMECS-CBP failed to show any enrichment. Since both libraries were comprised by 
the same Nbs, lack of enrichment on the one using pMECS-CBP might indicate a problem of 
expression, despite statements on the contrary 44.  
 
Figure 3.6 – LB Agar Amp/Glu plates that show enrichment after one round of panning with Nbs previously selected 
for human SIRPα. A – A conventional pMECS vector was used for the construction of the library Nbs against SIRPα. 
Positive results (Antigen incubated phages) are shown on the left side of the plate, while negative results (phages 
against empty well) are shown on the right side. B – New vector with a CBP tag was used for the construction of the 
library Nbs-CBP against SIRPα. Positive results (Antigen incubated phages) are shown on the left side of the plate, 
while negative results (phages against empty well) are shown on the right side.  
3.3 Periplasmic Expression and Purification of Nanobodies 
To better understand the lack of enrichment on phage display with Nbs previously selected to the 
target, expression of Nbs with and without the CBP tag was performed. Moreover, the Nb-CBP 
tags that might be produced, would later be used to evaluate if the capturing of the tagged Nb on 
CaM and its subsequent gentle release was efficient. Plasmid DNA of both pMECS and pMECS-
CBP was transformed into non-suppressor WK6 E. coli strain. In these cells the amber codon 
downstream of the His tag and upstream the gene for p III is recognized, therefore Nb is expressed 
as a protein and not fused to gene III protein 45. This is important because gene III protein can 
A B 
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cause false positives and might interfere with the Nb binding to its target. The Nbs were expressed 
as periplasmic proteins with the assistance of disulfide-bond catalysts, isomerases and chaperones 
by induction of the lac promoter with IPTG 53. The periplasmic extract was collected via an os-
motic shock and two purification steps were performed, IMAC followed by SEC. Although the 
CBP peptide is supposed to enhance the production yield 44, the amount obtained for CBP-tagged 
Nbs was far below 1 mg/L, while the same Nbs without the CBP could be express without any 
problems. Moreover, these Nbs could not be detected in any step of expression on western blot. 
Other attempts were made by adding lysozyme to improve the periplasmic extraction step. Even 
though the amount after IMAC was higher, when SEC was performed a higher number of con-
taminants was also revealed (Figure 3.7). Comparing all elution profiles of the different clones, it 
can be observed that even in well expressed Nbs, contaminants still elute earlier than the Nb, even 
if at a small scale. This observation is in accordance with the fact that IMAC is not sufficient to 
avoid the presence of protein contaminants 53. Moreover, at the time when imidazole is eluted, it 
causes a change in conductivity, represented by the orange line. In the cases where Nb is ex-
pressed with CBP, a seriously contaminated sample is noted and much less material at the elution 
time of Nb is observed.  
 
 
Figure 3.7 – Size Exclusion Chromatography of SH Nb 30 (A); SH Nb 30 extract using lysozyme for the improve-
ment of periplasmic extraction (B); SH Nb 30 CBP (C) and SH Nb 30 CBP with addition of lysozyme during 
periplasmic extraction (D). The blue line represents the elution profile of the proteins, whereas the orange represent 
the conductivity. 
An overview of the expression can be seen in Figure 3.8 and Figure 3.9. Aliquots of crucial steps 
during Nb expression and purification steps were loaded onto a polyacrylamide gel and proteins 
visualized after Coomassie staining or western blot for the detection of the Nb. As seen in Figure 
3.8, protein expression was obtained after IPTG induction. The periplasmic extract obtained by 
osmotic shock released a variety of proteins, which can be noted in the lanes 4 and 5 of the SDS-
PAGE. In the subsequent purification, a variety of proteins were being eliminated as noted in 
lanes 6 and 7, which correspond to the flow-through and wash of the IMAC. After IMAC elution, 
there were still some contaminating proteins present, as seen in lane 8. A further step of purifica-
tion was necessary to obtain pure Nbs. After SEC, lane 10, most of contaminants of higher MW 
were removed and the sample applied on gel in reducing conditions represents a pure Nb protein 
with MW of 15 kDa. In the western blot it can be seen that the Nb 30 was detected in all steps of 
expression and purification.  
A B 
C D 
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Figure 3.8 -  SDS gel  and western blot of the expression profile of SH30 and SH30 with addition of lysozyme for 
periplasmic extraction improvement. 1- positive control (SIRPα), 2- SH30 culture before induction, 3- SH30 culture 
after induction, 4- SH30 1st extraction, 5- SH30 2nd extraction, 6- SH30 wash PBS, 7-SH30 flow through, 8- SH30 
IMAC, 9- SH30 1st peak SEC, 10- SH30 2nd peak SEC, 11- marker, 12- marker, 13– SH30 Lysozyme 1st extraction, 
14- SH30 Lysozyme 2nd extraction, 15- SH30 Lysozyme flow through , 16- SH30 Lysozyme wash PBS, 17- SH30 
Lysozyme IMAC, 18- SH30 Lysozyme 1st peak SEC, 19- SH30 Lysozyme 2nd peak SEC, 20- SH30 Lysozyme 3rd 
peak SEC, 21- SH30 Lysozyme 4th peak SEC, 22- positive control (SIRPα). 
In the SDS-PAGE of Nb SH30 CBP (Figure 3.9), most of the earlier stages look similar to the Nb 
SH30, however, a band around the MW of the Nb is never observed. Since a positive control 
(human SIRPα containing a His tag) was added to the western blot, presence of a clear band 
indicated that the antibodies, conjugates and substrates we used were functional. Thus, not de-
tecting Nb SH30 CBP could be a sign that this Nb was not being properly expressed. 
A comparison between the amounts obtained for the Nb with and without CBP tag are shown in 
Table 3.1. Note that since nothing could be detected on western blot, measurements for the 
amount of SH Nb 30 CBP after SEC weren’t done. However, analyzing the data of SH Nb 30, 
there were indications that some Nb material was lost and that impurities were still present after 
IMAC. Moreover, measurements of concentration in a solution with imidazole are not the most 
accurate which can lead to overestimating the amounts after IMAC. 
Comparing the amounts obtained with and without the addition of lysozyme, as well as the SDS-
PAGE bands of 1st and 2nd extractions (5-6 with 13-14 of Figure 3.8), it was shown that lysozyme 
improved the periplasmic extraction step. 
Table 3.1 - Amounts obtained after IMAC and SEC of SH Nb 30, SH Nb 30 with periplasmic extraction enhance-
ment by the addition of lysozyme, SH Nb 30 CBP and SH Nb 30 CBP 30 with periplasmic extraction enhancement 
by the addition of lysozyme. 
Clone 
Amount (mg) ob-
tained after IMAC 
from 1 L culture  
Amount (mg) obtained after 
SEC from 1 L culture 
SH Nb 30 3.96 2.43 
SH Nb 30 + Lys 5.05 3.78 
SH Nb 30 CBP 0.63 Not applicable 
SH Nb 30 CBP + Lys 1.3 Not applicable 
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Figure 3.9 -  SDS gel and western blot of the expression profile SH30 CBP and SH30 CBP with addition of lysozyme 
for periplasmic extraction improvement. 1- positive control (SIRPα), 2- SH30CBP before induction, 3- SH30CBP 
after induction, 4- SH30CBP 1st extraction, 5- SH30CBP 2nd extraction, 6- SH30CBP flow through, 7- SH30CBP 
wash PBS, 8- SH30CBP Lysozyme 1st extraction, 9- SH30CBP Lysozyme 2nd extraction, 10- SH30CBP Lysozyme 
flow through, 11- SH30CBP Lysozyme wash PBS, 12- marker, 13- marker, 14- SH30CBP IMAC, 15- SH30CBP 
Lysozyme IMAC, 16- SH30CBP 1st peak SEC, 17- SH30CBP 2nd peak SEC, 18- SH30CBP 3rd peak SEC, 19- 
SH30CBP 4th peak SEC, 20- SH30CBP 5th peak SEC, 21 SH30CBP 6th peak SEC, 22- SH30CBP Lysozyme 1st 
peak SEC, 23- SH30CBP Lysozyme 2nd peak SEC, 24- SH30CBP Lysozyme 3rd peak SEC, 25- SH30CBP Lyso-
zyme 4th peak SEC, 26- positive control (SIRPα). 
To ensure that the expression of all Nbs is similar and to exclude that we choose by accident a 
poor expressing Nb, we tested the expression of 5 additional Nb clones, each of which was tagged 
with CBP. Table 3.2 summarizes the highest amount achieved of each tagged Nb, while using 
330 mL of medium. As observed in all attempts, it was not possible to detect Nbs in any step of 
the expression. 
Table 3.2 – Amount obtained after IMAC for each Nb fused to the CBP as measured by UV absorption at 280 nm. 
The extinction coefficient of the Nb predicted from the amino acid content was used to calculate those amounts. 
Clone 
Max amount (in mg) obtained after 
IMAC from 330 mL culture 
Extinction Coefficient 
(L/g.cm) 
SH Nb 30 CBP 0.43 1.636 
SH Nb 61 CBP 0.24 2.155 
SH Nb 67 CBP 0.48 1.853 
SH Nb 68 CBP 0.43 1.570 
SH Nb 69 CBP 0.29 1.922 
Sm Nb 75 CBP 0.44 1.636 
3.4 Re-Cloning of SIRPα mouse  
To better understand the expression problem, an Ag with high expression yield (mouse SIRPα) 
was re-cloned in the pMECS-CBP vector, using NotI and NcoI as restriction enzymes. After li-
gation, the construct was transformed into E. coli bacterial cells and a colony PCR using MP57 
and GIII was performed to select colonies with the right insertion (Figure 3.10).  
The Ag mouse SIRPα has a size of around 200 bp, meaning that right insertions had an expected 
size of 600 bp (lane 9, for example), while self-ligation of pMECS-CBP had an expected size of 
400 bp (lane 2, for example). From all re-cloning strategies this was the one with lower insertion 
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percentage. This could be explained by bad quality of DNA obtained during digestion, as shown 
in Figure 3.11, lane 3. The digested product didn’t show two clean bands, but rather a smear 
between the two bands of the expected size. Even though the percentage was low, sequencing 
confirmed that colonies with fragments around 600bp contained the right insert. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 – 1% agarose gel of  digestion profile of re-cloning mouse SIRPα into pMECS-CBP. 1 – DNA SmartLad-
der. 2 – Undigested  pHEN18 with SIRPα mouse. 3 – Digested pHEN18 with mouse SIRPα cut with NotI and NcoI, 
not purified. 4 - Digested pHEN18 with mouse SIRPα cut with NotI and NcoI, purified. 5 – Undigested pMECS-
CBP. 6 - Digested pMECS-CBP, cut with NotI and NcoI, not purified. 7 - Digested pMECS-CBP cut with NotI and 
NcoI, purified. 8 – ligation product pMECS- SIRPα-CBP. 
3.5 Periplasmic Expression and Purification of SIRPα mouse 
The vectors containing the mouse SIRPα were transformed into WK6 E. coli. The expression was 
initiated by the addition of IPTG to the culture, which promoted the production of SIRPα with 
and without the CBP tag. This antigen was chosen due to its high production yields. A significant 
drop in yield will be observed if the CBP was impeding the expression level. The SDS-PAGE 
results showed that SIRPα is present even at early stages of the expression and the SIRPα antigen 
was pure after IMAC (Fig 3.12). In contrast, a band corresponding to the size of SIRPα-CBP 
couldn’t be revealed, neither in Coomassie stained gels nor after western blot. This is similar to 
what we observed for Nb-CBP expressions. 
Figure 3.10 – A – DNA SmartLadder used as a marker for the size of the bands (expressed in bp). B – 1% agarose gel 
after colony PCR with primers MP57 and GIII to examine which have the mouse SIRPα insert. 1 DNA SmartLadder. 
2-17 Randomly selected WK6 E. coli colonies. 
A 
B 
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Figure 3.12 – Expression profiles of SIRPα mouse and SIRPα-CBP in bacterial periplasm. A – SDS-PAGE and west-
ern blot of SIRPα. 1 - Ladder, 2 – SIRPα before induction, 3 – SIRPα after induction, 4 – 1st extraction, 5 – 2nd ex-
traction, 6 – Flow through, 7 – Wash with PBS, 8 – IMAC, 9 – SEC, 10 – Positive control (SIRPα human). B – SDS-
PAGE and western blot of SIRPα-CBP. 1 – Ladder, 2 – SIRPα-CBP before induction, 3 – SIRPα-CBP after induc-
tion, 4 – 1st extraction, 5 – 2nd extraction, 6 – Flow through, 7 – Wash with PBS, 8 – IMAC, 9 – SEC 1st peak, 10 – 
SEC 2nd peak, 11 – positive control (SIRPα human). 
Comparing the elution profiles of SEC (Figure 3.13), a high peak corresponding to the Ag was 
noted, whereas multiple low intensity peaks were observed in case of SIRPα-CBP. A comparison 
between elution times of the Nbs and SIRPα is also feasible. SIRPα has a slightly lower MW 
compared to Nbs, thus it was expected to have a slightly longer retention time on the size exclu-
sion column. This was not observed, on the contrary. A faster elution for SIRPα than Nb could 
be explained if SIRPα does not have a globular shape, but an elongated architecture 55 with a 
larger hydrodynamic volume than the globular Nb.  
 
Figure 3.13 - Size Exclusion Chromatography of SIRPα mouse (A) and SIRPα-CBP 
The comparison of the amount of SIRP α and SIRPα-CBP, when produced in 1 L of media (Table 
3.3), revealed a sharp drop for the latter construct, which might indicate that CBP itself is respon-
sible for the obstruction of the recombinant protein.  
 
A 
B 
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Table 3.3 - Amounts obtained after IMAC and SEC of SIRP α and SIRPα-CBP 
Clone 
Amount (mg) ob-
tained after IMAC 
from 1 L culture  
Amount (mg) obtained after 
SEC from 1 L culture 
SIRPα mouse  8.75 4.56 
SIRPα mouse CBP 0.7 Not applicable 
3.6 Vectors and CBP Analysis 
After suspecting that the problem of expression might be caused by the CBP, further analysis 
were made. First all the vectors used were analyzed to verify if any other changes occurred while 
cloning was performed. A comparison between the original pMECS and pMECS-CBP can be 
seen in Figure 3.14, where it is noted that the only changes that occurred to the vector was the 
insertion of the CBP sequence (yellow region) comprised in the mutagenic primer used. The rest 
of the amino acids sequence was maintained, before and after the insertion. 
 
Figure 3.14 – Alignment of original pMECS and pMECS-CBP using CLC Main Workbench 9.9.1 software. 
A comparison between all pMECS-CBP vectors was also performed (Figure 3.15). In these, the 
insertions were made using NcoI and NotI as restrictions enzymes. As it was expected, the se-
quence differences occurred between those restriction enzymes, while the remaining sequence 
was conserved, including the CBP domain and the His tag used for purification and immunode-
tection of the proteins using western blot. Thus, a problem of expression due to incorrect assembly 
of the vectors is not probable. 
 
Figure 3.15 – Alignment of all pMECS-Nb-CBP and pMECS-SIRPa-CBP using CLC Main Workbench 9.9.1 soft-
ware. 
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Since the presence of CBP was likely causing the expression drop, we wonder whether it was the 
protein or the nucleotide sequence that was responsible. We, therefore, compared the coding se-
quences of our clones with that of a CBP tag that was described previously and that was reported 
to give good expression levels 44 (Figure 3.16).  
 
Figure 3.16 – Alignment of CBP used and CBP described in literature 44 using CLC Main Workbench 9.9.1 software. 
By comparing the sequence, it became apparent that even though both are encoding the same 
amino acid sequence, 5 nucleotide mutations were observed, two in Arginine, two in Alanine and 
one in Lysine codons. These different nucleotide sequences of the tag might cause a different 
mRNA secondary structure that prevents optimal translation 56. Alternatively, the preferred codon 
usage of E. coli could be responsible for the reduced expression as well 57. Among the rare codons 
are AGA and CGG, two codons that were occurring in our CBP design. Additionally, one of these 
Arginines is the first codon of the CBP peptide, which could be directly related to the expression 
problems encountered throughout the experiments. If this hypothesis is correct, then the design 
of a new mutagenic primer and consequently a new gene for the CBP tag might solve (or reme-
diate) the expression problems we encountered and might allow to proceed with this project.  
Although changes on the sequence were found, it is justified to question whether the problem 
could be related with the exportation of the Nb-CBP to the periplasm through the Sec pathway 58. 
If this was correct, a cytoplasmic expression should be performed, using a T7 expression vector 
without the peptide signal pelB. Even though the expression might be enhanced, another problem 
will rise using M13 bacteriophages for phage display. The propagation mechanism of M13 re-
quires that all components of the phage particle can be translocated across the bacterial inner 
membrane before they are assembled into the phage 59. Thus, if CBP could only be expressed in 
the cytoplasm, its exportation to the inner membrane would not be possible and enrichment by 
phage display would not occur and alternatives to this project needed to be found.
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4 Conclusions 
The aim of this master thesis was to develop a new phage display vector that would improve 
selection and screening methods of the technique. 
The first goal was to create a vector containing the CBP tag that would be compatible for phage 
display. To this end, the HA tag located downstream of the Nb cloning site present in pMECS-
GG was substituted by the CBP tag. Moreover, 6 Nbs with well-known and variable kinetic rates 
were also inserted into the pMECS-CBP vector. 
Next, the vector was used in a phage display setting, with already selected Nbs to verify that it 
could be used for biopanning.  For this purpose, two mini libraries comprising the 6 Nbs were 
made. One library was made with the conventional pMECS vector while the other was made 
using the pMECS-CBP vector. Although a 1000-fold enrichment on antigen was achieved using 
pMECS, the virions from pMECS-CBP failed to show any enrichment. After that failure, it was 
suspected that an expression problem might have occurred. 
Trying to express the Nbs with the CBP tag became a real challenge, especially because express-
ing them without the CBP tag was so easy and yielded around 3 mg/L of culture were observed. 
Several approaches were amended, such as adding lysozyme, to improve the periplasmic extrac-
tion step and expressing 5 different colonies to check for possible correlations. 
All these attempts failed to improve on the Nb expression. We therefore inserted a totally different 
protein in the CBP containing vector to discriminate between the Nb-CBP fusion and the CBP 
itself as the core of the expression problems. A high yield expressor (SIRPα) was cloned into the 
CBP vector. Even though SIRPα expressed at levels above 8 mg/L of culture, the expression from 
a vector that would attach a CBP at the recombinant protein suffered from a severe reduction in 
yield to a level below 1 mg per L of culture. 
A further analysis of the CBP tag was performed, following an alignment of our CBP sequence 
with that of a CBP tag, described to be an enhancer of expression. While having the same amino 
acid sequence, it was found that 5 codons differed, two Arginine codons, two Alanine codons and 
one Lysine codon. Moreover, among these codons were two codons rarely used in E. coli. We 
surmise that this unfortunate choice of codons might provoke a reduced expression noted in this 
thesis. 
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5 Future Perspectives 
Phage display is a widely used molecular screening technique for the selection of the Nb binders 
against a specific target. However, it still suffers from some drawbacks, such as limits of enrich-
ment that can be achieved per round of selection, undesired background created and a time-con-
suming screening to identify the Nbs with the best binding affinity. To solve these problems this 
thesis was created, however soon another problem came across us, expressing the CBP tag. 
Although the E. coli expression system is the most used for the production of proteins, it is still 
often that researchers find difficulties of expression 60. Factors that affect the processes of  tran-
scription, mRNA processing, translation, post-translational modification, protein folding and as-
sembly and protein expression can influence product yield 56. Moreover, most of the times, prob-
lems with the interference on processes of expression are related with the sequence of the protein 
expressed 50. In this case, we found that that could be the reason for the reduced expression noted 
throughout this thesis. Further steps could be the creation of a new CBP tag that was more E. coli 
friendly so that it could be expressed and used as a phage display vector. Another strategy could 
be changing the strain used for expression since some E. coli strains, such as Rosetta (DE3) from 
Novagen or BL21-CodonPlus from Stratagene, can supply tRNAs that recognize rare codons in 
the organism 61. However, to be used with this pMECS-CBP vector, these strains need to be able 
to suppress the amber codon present in this vector, while being used for phage display. 
After solving the problems of expression, the discovery of the best conditions, such as buffers, 
concentrations and incubation times, for the effective and efficient reversible binding between 
CaM and CBP is also crucial for the success of this project, since the only information known is 
that they bind in the presence of Ca2+ ions and are released in the presence of a calcium chelator, 
such as EDTA 44. 
Even though changes to the sequence were found, problems with secretion of the Nb-CBP to the 
periplasmic space through the Sec pathway could still be occurring. A cytoplasmic expression 
might solve the problem by using a T7 expression vector 58 62. In this system, T7 RNA polymerase 
is under the control of a pLac promoter in the host cells, such as BL21 (DE3), while the Nb-CBP 
should be under the control of a T7 promoter 61. After being induced by IPTG, T7 RNA polymer-
ase is expressed, thus the expression of Nb-CBP is also induced to the cytoplasm 61. If the cyto-
plasmic expression is efficient, the usage M13 bacteriophages for phage display may not be pos-
sible due to the requirement of all components of the phage particle in the inner membrane before 
assembly 59. Thus, if CBP could only be expressed in the cytoplasm, phage display using this 
vector might not be possible and other alternatives to this new phage display system should be 
found. 
Another direction could be using a different system that has the same features as the one presented 
here between CaM and CBP. A recently presented tag called ALFA-tag could be a good alterna-
tive, since it shows a reversible high affinity (nanomolar) with an engineered Nb 63. This affinity 
is reversible by the addition of free ALFA peptide 63.
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